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ABSTRACT
Acetate supplementation increases brain acetyl-CoA and attenuates
lipopolysaccharide (LPS)-induced neuroinflammation in vivo. To explain the antiinflammatory effect of acetate treatment, we proposed that acetate treatment disrupts
inflammatory signaling in microglia and astrocytes, and induces histone
hyperacetylation known to be correlated with anti-inflammatory properties. To test this
hypothesis, we measured the effects that LPS and acetate treatment had on histone
acetylation, mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NFκB), and eicosanoid signaling. A single oral dose of acetate treatment (6 g/kg) in
normal animals induced a time- and site-specific pattern of histone hyperacetylation,
associated with reduction of histone deacetylase (HDAC) activity and expression.
Long-term acetate treatment over 28 days induced the same site-specific pattern of
histone hyperacetylation, and reversed LPS-induced histone H3 at lysine 9 (H3K9)
hypoacetylation and interleukin (IL)-1β expression. In LPS-stimulated BV-2
microglia, acetate treatment reversed LPS-induced H3K9 hypoacetylation, IL-1β, IL-6,
tumor necrosis factor (TNF)-α, cyclooxygenase (Cox)-1 and 2 protein levels, and NFκB p65 protein level and phosphorylation at serine 468. Further, acetate treatment
increased IL-4 and transforming growth factor (TGF)-β1 expression, and NF-κB p65
acetylation at lysine 310. Conversely, acetate treatment did not alter LPS-induced

xv

cytosolic (c) phospholipase A2 (PLA2), transiently reduced MAPK p38 and JNK
phosphorylation, and increased MAPK ERK1/2 phosphorylation. In LPS-stimulated
astrocyte, acetate treatment induced H3K9 hyperacetylation, reversed LPS-induced
increases in IL-1β, TNF-α, NF-κB p65, and Cox-1 protein levels, MAPK p38 and
cPLA2 phosphorylation and PGE2 release, and reversed LPS-induced decreases in
TGF-β1 and IL-4. Moreover, acetate treatment reduced basal levels of IL-6,
phosphorylated ERK1/2 and NF-κB p65 at serine 536, sPLA2 IIA and PLCβ1. Acetate
treatment also increased acetylated H3K9 bound to the promoters of the genes of Cox1, Cox-2, IL-1β and NF-κB p65, but not IL-4 in BV-2 microglia, which suggests that
acetate treatment-induced H3K9 hyperacetylation can potentially be involved in the
alteration of the expression of these genes. These data suggest that acetate treatment
has net anti-inflammatory effects in vivo and in vitro both in LPS-stimulated microglia
and astrocyte cultures through neuroglial cell type-distinct mechanisms.

xvi

CHAPTER I
INTRODUCTION
Dietary Acetate Supplementation
Dietary acetate supplementation is a potentially effective therapy for the
treatment of Canavan disease; a human demyelinating disease (Arun et al. 2010b,
Madhavarao et al. 2009) and is effective at reducing the tremor phenotype in a rat
model of this disease (Arun et al. 2010b). Acetate supplementation is also effective at
maintaining adenosine triphosphate (ATP) levels in a rat model of traumatic brain
injury (Arun et al. 2010a) and reduces neuroglial activation and cholinergic
immunoreactivity in rats subjected to lipopolysaccharide (LPS)-induced
neuroinflammation (Reisenauer et al. 2011). In the brain, acetate is converted to
acetyl-CoA through the combined action of nuclear acetyl-CoA synthetase 1
(Ariyannur et al. 2010) and mitochondrial acetyl-CoA synthetase 2 (Fujino et al. 2001).
A single oral dose of glyceryl triacetate increases brain and liver acetyl-CoA levels by
2.2-and 2.6-fold, respectively (Reisenauer et al. 2011). Acetyl-CoA is a widely active
precursor in numerous biological processes that are central to mitochondrial energy
supply, fatty acid synthesis, and lipid metabolism (Deutsch et al. 2002). For example,
acetyl-CoA is used for oxidation in Krebs cycle and energy production after condensing
with oxaloacetate to form citrate (Des Rosiers et al. 1991, McGarry & Foster 1980).
Acetate can also be channeled into fatty acids and cholesterol synthesis, and when
1

present in excess as a result of an increase in fatty acid oxidation, acetyl-CoA can form
ketone bodies (Fukao et al. 2004).
Acetylation of Histone and Non-histone Proteins
Acetyl-CoA is utilized as a substrate for protein acetylation which is
increasingly appreciated as one of the major post-translational modification systems
with a wide range of histone and non-histone substrates. Non-histone targets of
acetylation include transcription factors, nuclear transport factors, cytoskeletal proteins
and many enzymes involved in diverse metabolic and signaling transduction pathways
(Polevoda & Sherman 2002). Acetylation of non-histones alters their subcellular
localization, DNA binding, transcriptional activity, protein-protein interaction, and
protein stability (Glozak et al. 2005).
Another major target of acetylation is histone proteins which are instrumental in
the packaging of DNA and play a central role in transcription regulation. There are five
isoforms of histones: H1, H2A, H2B, H3 and H4. The basic structural unit of
eukaryotic chromosomes is a DNA-protein complex called the nucleosome which
consists of a DNA molecule associated with a histone octamer comprised of pairs of the
core histones H2A, H2B, H3 and H4. The nucleosomes are joined by linker DNA and
histone H1 to form chromatin, and each chromosome can accommodate 147 base pairs
of DNA. Each core histone has a globular region and a histone fold domain which is
involved in histone-histone interactions (Arents et al. 1991) and the wrapping of DNA
around the nucleosome core (Luger et al. 1997). The N-terminal tail regions extend
outside of the nucleosome particle where they can interact with DNA and with other
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regulatory proteins or transcription factors (Baneres et al. 1997, Bradbury 1992, Luger
et al. 1997). Acetylation of the lysine residues on the N-terminal tail of histones
neutralizes the positive charge on the lysine residue and reduces histone-DNA binding.
The reduction in histone-DNA binding increases the accessibility of chromatin by
transcription machinery (Anderson et al. 2001, Gorisch et al. 2005, Polach et al. 2000).
Hyperacetylated nucleosomes also increase the flexibility of the DNA associated with
the end of the nucleosomes, which is proposed as an additional way histone acetylation
can alter gene expression (Krajewski & Becker 1998). Histone acetylation and
methylation sites are recognized by proteins that have bromo- and chromo-domains
respectively. Therefore, covalently modified histone serve as marks for binding sites to
recruit other proteins that facilitate downstream events resulting in altered gene
expression (Mu et al. 2007). The multitude of events and changes that take place
during transcription are thus not due only to histone acetylation changes, but represents
the outcome of synergistic actions of several factors (Eberharter & Becker 2002).
The acetylation of histone H4 is restricted to lysines 5, 8, 12, and 16 (H4K5,
H4K8, H4K12 and H4K16, respectively) (Clarke et al. 1993). Another known posttranslational modification of histone H4 is methylation, restricted to lysine 20 (Borun et
al. 1972), which precludes acetylation at this site (Annunziato et al. 1995). Random
histone acetylation would yield four mono-acetylated isoforms: acetylated H4K5,
H4K8, H4K12 or H4K16, six di-acetylated isoforms: H4K5/H4K8, H4K5/H4K12,
H4K5/H4K16, H4K8/H4K12, H4K8/H4K16 and H4K12/H4K16, four tri-acetylated
isoforms: H4K5/H4K8/H4K12, H4K5/H4K12/H4K16, H4K8/H4K12/H4K16, and
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H4K5/H4K8/H4K16, and one tetra-acetylated isoform. The most common monoacetylated form is that of lysine 16 (Zhang et al. 2002). Histone H3 can be acetylated
at lysines 9, 14, 18 and 23, of which the acetylation at lysines 9 and 14 is better
understood (Sterner & Berger 2000), and can be methylated at more numerous sites
including lysines 4, 9, 27, 36 and 79, and arginines 2, 17 and 26 (Mu et al. 2007). H2A
has the largest number of variants including H2A.Z, MacroH2A, H2A-Bbd, H2AvD,
and H2A.X which are classified based on the C-terminal sequence and length, and
genomic distribution (Redon et al. 2002). H2B has a few variants with largely
unknown roles, even though they have specialized functions in chromatin compaction
and transcription repression during gametogenesis (Green et al. 1995). The
involvement of histones H2A and H2B in inflammation is less clear than histones H3
and H4. A pubmed search using the keywords “H3 and H4 and inflammation”
retrieves 54 articles, whereas using the keywords “H2A and H2B and inflammation”
retrieves only 3 references. We therefore chose to focus on changes in histones H3 and
H4, but this does not exclude the possibility of acetate treatment inducing covalent
modifications in histones H2A and H2B with potential functional consequences.
Histone proteins can also be modified by phosphorylation, ADP-ribosylation,
glycosylation and ubiquitination although the most well studied modifications are
acetylation and methylation (Mu et al. 2007). Throughout our studies, we focused on
acetylation changes in histones which are more likely to result from altering the level of
the acetyl group donor acetyl-CoA after acetate treatment.

4

Site-specific acetylation patterns have been linked to both physiological and
pathological roles. For example, histone H4 acetylated at lysine 16 (H4K16) is
essential for transcription initiation (Shogren-Knaak et al. 2006) and DNA repair (Li et
al. 2010). Histone H3 acetylated at lysine 9 (H3K9) is selectively enriched at the
promoters of stem cells, suggesting a role in pluripotency (Hezroni et al. 2011).
Alterations in histone acetylation state are involved in many physiological processes
including normal development (Shi & Wu 2009), cell differentiation (Haumaitre et al.
2009), memory formation (Peleg et al. 2010, Levenson et al. 2004), cellular lifespan
(Dang et al. 2009), synaptic plasticity (Vecsey et al. 2007, Guan et al. 2009, Sharma
2010), and modifications of embryonic neuron differentiation (Balasubramaniyan et al.
2006). Therapeutically, increases in histone acetylation are associated with
neuroprotective properties in animal models of cerebral ischemia (Kim et al. 2007), and
amyotrophic lateral sclerosis (Rouaux et al. 2007), and reduce microglial activation in
traumatic brain injury (Zhang et al. 2008). Furthermore, oxidative stress-induced
apoptosis, a hallmark of many neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, stroke, and multiple sclerosis, is reduced
upon treatment with histone deacetylase (HDAC) inhibitors suberoylanilide
hydroxamic acid (SAHA) and trichostatin A (TSA) which lead to histone
hyperacetylation (Ryu et al. 2003). Similarly, HDAC inhibitors decrease
polyglutamine toxicity in a mouse motor neuron–neuroblastoma fusion cell line
(McCampbell et al. 2001) and in Drosophila models of polyglutamine diseases (Steffan
et al. 2001). All of which suggests a loss of neuronal function during
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neurodegeneration can be restored by increasing histone acetylation. The histone
acetylation state is actively maintained by the opposing activities of two enzyme
families: histone acetyltransferases (HATs) and HDACs. Based on structural
homology, HDACs are classified into different classes: HDAC class I is mainly located
in the nucleus, HDAC class II shuttles between the nucleus and cytoplasm, and HDAC
class III (sirtuins) are located in the cytoplasm (de Ruijter et al. 2003). HDAC classes I
and II are inhibited by conventional HDAC inhibitors, while class III HDACs are
nicotinamide adenine dinucleotide (NAD+)-dependent and inhibited by nicotinamide
(Avalos et al. 2005). Likewise, HATs are classified into distinct families (general
control non-derepressible 5 (GCN5), P300/cyclic adenosine monophosphate response
element binding protein associated factor (PCAF), the MYST family named for its
founding members in yeast and mammals, monocytic leukemia zinc finger protein
(Moz), Something About Silencing protein (Sas2p), and HIV tat-interacting protein 60
(Tip60), transcription initiation factor TFIID 250 kDa subunit (TAFII250), steroid
receptor coactivator proteins (SRC), and GCN5-related N-acetyltransferase (GNAT))
that show high sequence similarity within families, but poor-to-no sequence similarity
between families (Marmorstein & Roth 2001). The exact correlation of individual
HATs or HDACs with site-specific acetylation or deacetylation of histone lysine
residues remains largely unknown due to overlapping enzyme targets (Howe et al.
2001, Kuo et al. 1996).

6

Neuroinflammation
Neuroinflammation, an innate immune response characterized by the release of
a repertoire of inflammatory mediators including cytokines, is advantageous with
regard to normal brain physiology. However, excessive and persistent
neuroinflammation is detrimental and associated with numerous neurological
pathologies (Glass et al. 2010, Mrak 2009). Cytokines have pleiotropic physiological
functions that include regulating cell growth, survival, differentiation, and activities
(Hopkins & Rothwell 1995, Rothwell & Hopkins 1995). Cytokine release can lead to
either beneficial or deleterious outcomes depending on the dose, time and duration of
secretion, and cellular target leading to enhanced cellular viability or further damage,
respectively (Suzuki et al. 2009). Under normal conditions, cytokines serve as
communication signals among different cell types in the brain, but contribute to
bystander neuronal lysis in uncontrolled neuroinflammation (Tian et al. 2012).
Excessive pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin
(IL)-1β, and IL-6 are involved in the pathogenesis of neuroinflammatory and
neurodegenerative disease states such as acute cerebral ischemia (Denes et al. 2010),
Alzheimer’s disease (Johnston et al. 2011, Shaftel et al. 2008), Parkinson’s disease
(Qian et al. 2010), multiple sclerosis (Merson et al. 2010) and traumatic brain injury
(Helmy et al. 2011). Therefore, disrupting pro-inflammatory cytokine signaling is
commonly proposed as a therapeutic target. In contrast, anti-inflammatory cytokines
include transforming growth factor-beta1 (TGF-β1), IL-4 and IL-10 which obviate the
potential of injury due to excessive or uncontrolled inflammatory reactions through
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downregulating the pro-inflammatory cytokines and induction of tissue repair
(Ledeboer et al. 2000, Vitkovic et al. 2001). A dynamic balance exists between the
pro- and anti-inflammatory cytokines, both of which are generated upon exposure to
injury or infection. The duration and net effect of interactions between these opposing
molecular groups determines the outcome of the immune response. Pathologies arise
from shifting this dynamic balance in one direction or the other. For example,
excessive pro-inflammatory cytokines are linked to neuroinflammation and
degeneration as mentioned earlier, while excessive anti-inflammatory cytokines are
conversely associated with susceptibility to systemic infections (Kasai et al. 1997,
Munoz et al. 1991).
Lipopolysaccharide-induced Neuroinflammation
A well-established method of inducing neuroinflammation experimentally is
through the use of LPS in whole animals or in cell cultures. LPS, an endotoxin present
in the membrane of Gram-negative bacilli, binds to toll-like receptor 4 (TLR-4) found
on many brain cell types and promotes an inflammatory response characterized by
enhanced expression of the pro-inflammatory cytokines, neuroglial activation and
neurodegeneration, and increased turnover and metabolism of brain arachidonic acid.
The activities of both arachidonic acid-selective secretory (s) and cytosolic
phospholipases A2 (cPLA2) also increase as do the levels of prostaglandins E2 and D2
(PGE2 and D2) with LPS stimulation. Thus, this model reproduces many of the
properties associated with known modalities of neuroinflammation (Aravalli et al.
2007, Hauss-Wegrzyniak et al. 1998a, Hauss-Wegrzyniak et al. 1998b, Hauss-
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Wegrzyniak et al. 2000, Lehnardt 2010, Lehnardt et al. 2003, Reisenauer et al. 2011,
Rosenberger et al. 2004). LPS infusion through a cannula implanted into the fourth
ventricle of the brain and connected to a subcutaneous mini-osmotic pump is
commonly used as a model to study neuroinflammation in vivo (Hauss-Wegrzyniak et
al. 1998a, Hauss-Wegrzyniak et al. 1998b, Hauss-Wegrzyniak et al. 2000, Reisenauer
et al. 2011, Rosenberger et al. 2004).
Microglia and Aastrocytes in Physiology and Neuroinflammation
Microglia are the primary resident immune cells of the central nervous system
that, under normal conditions, monitor the brain for any changes in the environment.
When the structural or functional integrity of the brain is disturbed, microglia change
into a more reactive phenotype characterized by microglial hypertrophy, loss or
shortening or cellular processes, increased secretion of inflammatory mediators and
enhanced phagocytic activity (Hanisch 2002, Hanisch & Kettenmann 2007, Lehnardt
2010, Lehnardt et al. 2003, Olson & Miller 2004, Ransohoff & Perry 2009, Streit et al.
1999). The BV-2 mouse microglia cell line, immortalized through oncogenes-carrying
retrovirus, exhibit morphological, functional, and phenotypical properties similar to
primary microglia (Blasi et al. 1990, Bocchini et al. 1992). Therefore, BV-2 microglial
cells are commonly used as an alternative to primary microglia to study various
microglial responses and interactions (Petrova et al. 1999, Rojanathammanee et al.
2011, Woo et al. 2003). Astrocytes are the most abundant cell type in central nervous
system with essential functions in maintaining the blood-brain barrier, synaptic
plasticity, provision of metabolites to neurons, and neurotransmitters homeostasis
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(Sadoul et al. 2008, Sofroniew & Vinters 2010). Being connected via gap junctions, in
injury and infections, astrocytes distribute many mediators that contribute to either
detrimental or beneficial consequences (Frantseva et al. 2002, Nakase et al. 2003). In
inflammatory conditions, astrocytes undergo reactive astrogliosis characterized by
astrocytic hypertrophy, upregulation of intermediate filaments like vimentin and glial
fibrillary acidic protein (GFAP), altered molecular expression profile, and scar
formation (Kang & Hebert 2011, Pekny & Nilsson 2005, Sofroniew 2009). Although
essential for proper tissue healing, excessive astrocytic reactivity contributes to the
inflammatory response through production to numerous pro-inflammatory cytokines
(Dong & Benveniste 2001, Gorina et al. 2011, Gorina et al. 2009) and are thus
recognized as a potential target of therapeutics in many neurological disorders (Hamby
& Sofroniew 2010).
Mitogen-activated Protein Kinases and Nuclear Factor-kappa B Signaling
Mitogen-activated protein kinases (MAPK) p38, c-Jun N-terminal kinase (JNK)
and extracellular signal-regulated kinase (ERK) have a crucial role in the regulation of
the immune and inflammatory responses, cell differentiation and survival, and the
response to stress. MAPK are key regulators of the biosynthesis of pro-inflammatory
cytokines TNF-α, IL-6 and IL-1β and are hence potential therapeutic targets in
inflammatory and autoimmune diseases (Kumar et al. 2003, Pearson et al. 2001).
When activated by phosphorylation, MAPK signaling upregulates the biosynthesis of a
number of inflammatory mediators including the pro-inflammatory cytokines
(Kaminska et al. 2009, Pearson et al. 2001). Interestingly, a certain lysine acetylation
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in MAPK phosphatase-1 leads to its activation, which subsequently dephosphorylates
and inactivates MAPK signaling (Cao et al. 2008). This provides an important link
between acetylation and phosphorylation in the regulation of inflammatory signaling.
Nuclear factor-kappa B (NF-κB) is another major regulator of inflammatory and
immune responses downstream of TLR-4 receptors. NF-κB is a heterodimer of two
subunits; most commonly p65 and p50, combined in the cytosol with inhibitors of
kappa B (IκB) which mask the nuclear export motif, leading to NF-κB inactivity. Upon
stimulation by pro-inflammatory cytokines, B and T cell receptor signaling, and viral
and bacterial toxins, NF-κB is released from IκB and translocates to the nucleus where
it binds DNA sequences and alters the transcriptional activity of genes involved in
inflammatory responses and cell survival (Chen & Ghosh 1999, DiDonato et al. 2012,
Schmitz et al. 2004). p65, but not p50, binds transcriptional co-activators p300 and
CREB-binding protein (Perkins et al. 1997) and can be modified by acetylation at
certain lysine residues with variable functional outcomes in terms of the affinity to IκB,
nuclear translocation, DNA binding and transcriptional activity (Chen & Ghosh 1999,
Chen et al. 2001, Chen et al. 2002, Huang et al. 2010a, Kiernan et al. 2003).
Therefore, both MAPK and NF-κB signaling pathways are important players in
inflammation that can be regulated by acetylation.
Eicosanoid Signaling
Phospholipases are a heterogeneous group of enzymes which catalyze the
hydrolysis of fatty acids esterified to membrane phospholipids and release free fatty
acids and lysophospholipids. The action of cyclooxygenases-1 and 2 (Cox-1 and 2) on
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arachidonic acid, released from the sn-2 position of membrane phosphatidyl choline by
the action of PLA2, leads to the release of prostaglandins (PGs) (Smith et al. 2000).
PLA2 groups are classified into cytosolic (c) PLA2 and secretory (s) PLA2 which
require calcium for activity, and calcium-independent PLA2 (iPLA2) (Balboa et al.
2002, Dennis 1994). sPLA2 is divided into type I (also called pancreatic type) and type
II (also called inflammatory type) (Sun et al. 2010), the most well studied of which is
type IIA sPLA2 expressed in most areas of rat brain and whose levels are elevated after
inflammatory conditions like ischemia and endotoxic shock (Fujimori et al. 1992,
Lauritzen et al. 1994). PLCs, structurally divided into PLCβ, γ, δ, and ε, hydrolyze
fatty acids esterified at the sn-3 position of phosphatidyl inositol 4, 5-bisphosphate to
release diacyl glycerol and inositol 1, 4 and 5- trisphosphate which eventually increase
intracellular calcium and activate protein kinase C (Farooqui & Horrocks 2005). The
physiological functions of phospholipases in the brain include phospholipid
metabolism, exocytosis, removal of phospholipid peroxides, neurotransmitter release,
long-term potentiation, neural cell proliferation, and the release of neurotransmitters
(Farooqui et al. 1997, Balboa et al. 2002, Dennis 1994). Eicosanoid signaling is
upregulated by LPS, pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, NF-κB, and
MAPK p38, ERK and JNK, all of which are major players in neuroinflammation
(Farooqui & Horrocks 2005, Sun et al. 2010, Fujimori et al. 1992, Lauritzen et al. 1994,
Lima et al. 2012, Phillis & O'Regan 2004, Farooqui et al. 1997, Smith et al. 2000,
Balboa et al. 2002, Dennis 1994, Hiller & Sundler 1999, Kramer et al. 1996, Adibhatla
& Hatcher 2007, Jupp et al. 2003). cPLA2 is activated by phosphorylation, especially
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by MAPK, which is followed by translocation from the cytosol to the membrane (Hiller
& Sundler 1999, Kramer et al. 1996). In pathological conditions, phospholipases and
eicosanoid signaling has a role in neuronal injury because of altered membrane
permeability, accumulation of free fatty acids and lipid peroxides and are therefore
involved in a number of neuroinflammatory and degenerative conditions (Lima et al.
2012, Phillis & O'Regan 2004).
Our Work and Findings
Acetate supplementation increases plasma and tissue levels of acetate and brain
levels of acetyl-CoA, and attenuates LPS-induced microglia and astroglial activation
and the loss of cholinergic immunoreactivity in a rat model of neuroinflammation
(Reisenauer et al. 2011). In addition, acetate treatment is effective therapy for the
treatment of a human demyelinating disease Canavan disease (Arun et al. 2010b,
Madhavarao et al. 2009) and is effective at reducing the tremor phenotype in a rat
model of this disease (Arun et al. 2010b). Acetate supplementation is also effective at
maintaining ATP levels in a rat model of traumatic brain injury (Arun et al. 2010a) .
This body of work represents an attempt to understand the mechanisms of the antiinflammatory effects of acetate supplementation in inflammation. No reports are
available that describe a decline in brain acetate levels in response to LPS or
neurological pathologies. Consequently, rather than replenishing endogenous acetate
stores, we propose that acetate supplementation acts to increase intracellular levels of
acetyl-CoA as an inducer of metabolic and molecular processes that ultimately result in
the reduction of inflammatory phenotype. Our overall hypothesis is that acetate
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treatment in in vivo and in vitro models of inflammation shifts the cytokine balance
toward a more anti-inflammatory state and disrupts inflammatory signaling, which is
associated with acetylation of histone and non-histone targets. To begin to test this
hypothesis, we tested the effect that a single oral dose of glyceryl triacetate, used to
induce acetate supplementation, has on brain histone acetylation. We treated normal
rats once with oral gavage of 6 g/kg glyceryl triacetate and used Western blot analysis
to determine the level of acetylated histone H3 at lysine 9 and 14 (H3K9 and H3K14),
and histones H4 at lysine 5, 8, 12 and 16 (H4K5, H4K8, H4K12 and H4K16). We
chose this dose of glyceryl triacetate based on earlier reports showing that this is the
dose that leads to the highest increase in plasma and tissue acetate levels (Mathew et al.
2005). Our goal was to induce the highest possible acetyl-CoA level derived from
acetate treatment to identify the metabolic and inflammatory processes that can be
modulated downstream to acetyl-CoA formation. Thereafter, the dose of acetate can be
scaled down to determine the smallest acetate concentration that still leads to the
desired therapeutic effects. We found that acetate treatment induced a pattern of siteand time-specific histone hyperacetylation in the brain. Acetate supplementation
increased the acetylation state of brain H4K8 at 2 and 4 h, H4K16 at 4 and 24 h, and
H3K9 at 4 h following treatment. No changes in other forms of brain H3 and H4
acetylation state were found at any post-treatment times measured. To determine the
mechanism by which a single acetate supplementation alters histone acetylation, we
measured the effect of a single acetate treatment on the HAT and HDAC enzymic
activities. We found that while HAT activity was not altered by a single oral dose of
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acetate treatment, HDAC activity was reduced at 2 and 4 hrs that was associated with
reduced HDAC2 protein level. Based on these data, we conclude that a single oral dose
of acetate supplementation can indeed alter histone acetylation, which is mainly due to
reduction in HDAC activity.
The hypothesis that long-term acetate supplementation reverses LPS-induced
histone acetylation changes and pro-inflammatory expression in the brain, proceeded to
be tested. The objective of this study was to demonstrate the association of histone
hyperacetylation with functional consequences in terms of alteration of inflammatory
gene expression in a rat model of neuroinflammation. Sprague-Dawley rats underwent
surgeries to install LPS or artificial cerebrospinal fluid (aCSF) subcutaneous
minipumps connected to a cannula implanted into the 4th ventricle. Afterwards,
animals were treated orally daily with either water or glyceryl triacetate (6 g/kg). After
28 days of treatment, animals were killed and the brains were collected. Using Western
blot analysis, we measured histone acetylation changes as well as the expression of IL1β protein. Parallel studies were performed to quantify IL-1β mRNA using quantitative
real-time polymerase chain reaction (qrt-PCR). We found that long-term acetate
supplementation increased the proportion of brain H3K9, H4K8 and H4K16, similar to
that found with a single oral dose. However, unlike a single dose of glyceryl triacetate,
long-term treatment increased HAT activity and had no effect on HDAC activity, with
variable effects on brain HDAC class I and II expression. In agreement with our
hypothesis, neuroinflammation reduced the proportion of brain H3K9 acetylation by
50%, which was effectively reversed with acetate supplementation. Further, in rats
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subjected to LPS-induced neuroinflammation, IL-1β protein and mRNA levels were
increased by 1.3- and 10-fold, respectively, and acetate supplementation reduced this
expression to control levels. Based on these results, we conclude that dietary acetate
supplementation effectively reduces pro-inflammatory cytokine expression by a
mechanism that may involve a distinct site-specific pattern of histone acetylation in the
brain.
An in vitro system that is conducive to examining the effect of acetate treatment
on certain inflammatory signaling pathways in primary and BV-2 microglia and
primary astrocyte cultures was then designed. We proposed that in microglia and
astrocytes, acetate supplementation reverses LPS-induced changes in histone
acetylation, pro- and anti-inflammatory cytokines, and MAPK, NF-κB, and eicosanoid
signaling. In order to test that, we measured the effects of LPS and acetate treatment on
the proportion of acetylated H3K9, the expression of IL-1β, IL-6, TNF-α, TGF-β1, IL-4
and IL-10, the phosphorylation of MAPK p38, JNK and ERK1/2, NF-κB p65 total
protein and modification, cPLA2 phosphorylation, the protein levels of sPLA2 IIA,
PLCβ1, PLCγ1, PLCδ1, Cox-1 and Cox-2, and the release of PGE2. We treated
primary microglia for 4 hours with either 6.25 ng/ml LPS and/or 12 mM sodium acetate
and compared the results to 12 mM NaCl as a control group. The rationale for using
this acetate concentration is based on unpublished data showing that 12 mM sodium
acetate is the highest concentration that does not cause significant cell death compared
to cells grown in serum-free media. The rationale for using this LPS concentration is
based on the dose-response study showing that this LPS concentration produced 50%

16

H3K9 hypoacetylation in microglia similar to that found in vivo, and increased all the
pro-inflammatory cytokines measured in microglia. NaCl was used as a control group
as well as together with LPS treatment to make sure all treatment groups had similar
osmolarity to that of 12 mM sodium acetate. Acetate supplementation increased H3K9
acetylation starting at 2 hours in BV-2 microglia and at 1 hr in astrocytes, so we chose
4 hr for later treatments to ensure protein expression after treatment.
We observed distinct neuroglial-cell type specific differences both with acetate
treatment and LPS challenge. In LPS-stimulated microglia, acetate treatment induced
H3K9 hyperacetylation and reversed LPS-induced H3K9 hypoacetylation similar to
that found in vivo. LPS also increased IL-1β, IL-6 and TNF-α mRNA and protein,
while acetate treatment returned the protein to control levels and only partially
attenuated IL-6 mRNA. In contrast, acetate treatment increased mRNA levels of TGFβ1 and both IL-4 mRNA and protein. LPS increased p38 MAPK and JNK
phosphorylation at 4 and 2-4 hr respectively, while acetate treatment reduced p38
MAPK and JNK phosphorylation only at 2 hr. In addition, acetate treatment reversed
the LPS-induced elevation of NF-κB p65 protein and phosphorylation at serine 468 and
induced hyperacetylation at lysine 310. Acetate treatment did not alter the LPSinduced 1.7-fold increase in the cPLA2 phosphorylation, reversed to control levels the
LPS-induced 2-fold reduction in PLCβ1 protein levels and 1.5-fold increase in Cox-1
protein level, and only partially attenuated the LPS-induced 4-fold increase in Cox-2
protein level. The protein levels of total cPLA2, sPLA2 IIA, PLCγ1 and PLCδ1, and
PGE2 release were not altered by either acetate treatment or LPS. Because acetate
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treatment induces H3K9 hyperacetylation, reverses LPS-induced H3K9
hypoacetylation, and alters inflammatory gene expression in vivo (Soliman et al.
2012b) and in vitro (Soliman et al. 2012a), we proposed that acetate treatment increases
the enrichment levels of acetylated H3K9 at the promoters of Cox-1 and 2, NF-κB, proinflammatory cytokine IL-1β and anti-inflammatory cytokine IL-4. Using chromatin
immunoprecipitation analysis in LPS-stimulated BV-2 microglia, acetylated H3K9 was
found to be increased with acetate treatment at the promoter regions of these genes
except IL-4. It is therefore possible that acetate treatment-mediated increase in
acetylated H3K9 bound to the promoters of certain inflammatory genes is potentially
involved in altering their expression. These data suggest that acetate metabolism shifts
inflammatory cytokine balance toward an anti-inflammatory state, alters the levels of
enzymes involved in eicosanoid signaling, and possibly disrupts NF-κB signaling,
which is associated with histone and non-histone protein hyperacetylation in LPSstimulated microglia.
Using primary astrocyte cell cultures, we found that LPS (0-25 ng/ml, 4 hr)
increased TNF-α and IL-1β in a concentration-dependent manner, which was reduced
by treatment with sodium acetate (12 mM). LPS did not alter H3K9 acetylation or IL-6
levels, whereas acetate treatment increased H3K9 acetylation and decreased basal
levels of IL-6. Acetate treatment attenuated the LPS-induced increase in TNF-
mRNA, but did not reverse the mRNA levels of other pro-inflammatory cytokines. By
contrast, LPS decreased TGF-β1 and IL-4 protein and TGF-β1 mRNA, all of which
was reversed with acetate treatment. Further, acetate treatment completely reversed
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LPS-induced phosphorylation of MAPK p38 and decreased basal levels of
phosphorylated extracellular signal-regulated kinases1/2 (ERK1/2). Acetate treatment
also reversed LPS-elevated NF-κB p65 protein level and reduced basal levels of
phosphorylated NF-κB p65 at serine 536. Moreover, acetate treatment reversed to
control levels the LPS-induced 2-fold increase in cPLA2 phosphorylation and the 1.5fold increase in Cox-1 protein level, and decreased those of sPLA2 IIA and PLCβ1
below control levels only in the presence of LPS. Acetate treatment decreased basal
levels of Cox-2 by 2-fold only in the absence of LPS and had no effect on LPS-induced
3-fold increase in Cox-2 protein levels. The protein levels of total cPLA2, PLCγ1 and
PLCδ1 were not altered by either acetate treatment or LPS. Acetate treatment reversed
to control levels the LPS-induced 4-fold increase in PGE2 release. These results
suggest that acetate treatment shifts the inflammatory cytokine balance toward an antiinflammatory state, which is associated with histone hyperacetylation and a disruption
in MAPK, eicosanoid and possibly NF-κB signaling in LPS-stimulated primary
astrocytes. Overall, these data suggest that acetate treatment has net anti-inflammatory
effects in vivo and in vitro both in LPS-stimulated microglia and astrocyte cultures
through neuroglial cell type-specific mechanisms, most notably of which is the reversal
of LPS-induced p38 and cPLA2 phosphorylation and PGE2 release, and reducing basal
levels of phosphorylated ERK1/2 in astrocytes.
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CHAPTER II
METHODS
Reagent
Antibodies against acetylated H3K9, acetylated H3K14, total histone H3, total
histone H4, acetylated histone H4K5, H4K8, H4K12 and H4 K16 were obtained from
Upstate Biotechnology (Lake Placid, NY). Antibodies against HDAC1, 2, 3, 4, 5 and 7
were obtained from Cell Signaling Technology Inc. (Danvers, MA). Mouse
monoclonal antibody against α-tubulin and goat anti-mouse IgM secondary antibody
conjugated with horse radish peroxidase were from Santa Cruz Biotech. Inc. (Santa
Cruz, CA). Antibodies against phosphorylated p38 (Thr180/Tyr182), total p38,
phosphorylated JNK (Thr183/Tyr185, Thr221/Tyr223), phosphorylated ERK1/2
(Th202/Tyr204, Thr185/Tyr187), and ERK1/2 were from Millipore (Billerica, MA),
and anti-JNK and NF-κB p65 antibodies were purchased from Cell Signaling
Technology Incorporated (Danvers, MA). Rabbit polyclonal antibodies to IL-1β, IL-6,
TNF-α, TGF-β1, IL-4, IL-10 and acetyl-CoA synthetase, and HAT activity assay kit
were from Abcam (Cambridge, MA). All Western blot supplies and a goat anti-rabbit
horseradish peroxidase-linked antibody were obtained from Bio-Rad Laboratories
(Hercules, CA). Glyceryl triacetate was purchased from Sigma (St. Louis, MO).
Reverse and forward IL-1β, IL-6, TNF-α , IL-4, IL-10, TGF-β1 and β-actin primers for
real-time polymerase chain reaction (qrt-PCR) from SA Biosciences (Frederick, MD),
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FastStart Universal SYBR Green Master from Roche Applied Science (Indianapolis,
IN), TRIzol® reagent from Life Technologies (Grand Island, NY), the RT² Profiler™
PCR Array was from SABiosceinces (Valencia, CA), nuclease-free water was
purchased from Gibco, Life Technologies (Grand Island, NY), and DMEM–F-12 media
and fetal bovine serum were from Invitrogen (Grand Island, NY). LPS (Escherichia
Coli 055:B5) and proteinase K were purchased from Sigma (St. Louis, MO), antibodies
against PLCβ1, γ1, δ1, cPLA2 from Santa Cruz Biotechnology Inc. (Santa Cruz, CA),
antibodies against Cox-1, Cox-2 and sPLA2 IIA, and prostaglandin screening EIA kit
from Cayman Chemical Company (Ann Arbor, MI), and RNAse A from Invitrogen
(Grand Island, NY). Chromatin immunoprecipitation assay kit, antibodies against
acetylated H3K9 and normal rabbit IgG, and HDAC activity assay kit were purchased
from Millipore (Billerica, MA), QIAquick PCR purification kit from Qiagen (Valencia,
CA), protein A and protein G magnetic beads from Invitrogen (Grand Island, NY),
complete EDTA-free protease inhibitor cocktail tablets from Roche Applied Science
(Indianapolis, IN). All chromatin immunoprecipitation primers (table 1) were ordered
from Integrated DNA Technologies (Coraville, IA). All buffering reagents and other
chemicals were purchased from EMD Biosciences (Gibbstown, NJ).
Animals
All rats used conformed to the Guide for the Care and Use of Laboratory
Animals (NIH publication number 80-23) as approved by the University of North
Dakota animal care and use committee. Male Sprague-Dawley rats (220-300 g, Charles
River Laboratories, Portage, MI) were allowed to acclimate in our facility for at least
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two weeks prior to inclusion in the study and were maintained on a constant 12-hour
light cycle and fed a standard lab chow (Purina 2018 Tekled Global) ad libitum. Oral
glyceryl triacetate (6 g/kg) was used to induce acetate supplementation using feeding
tubes (Instech, Solomon, PA) in rats that were starved for at least 12 hours before
treatment to normalize circulating levels of glucose and fatty acids (Kargas et al. 1990).
The rats were divided into six different groups (n = 6 per group). Groups one through
five (GTA-treated) were given a single oral dose of glyceryl triacetate while control
rats were given a single oral dose of water (6 g/kg).
Induction of Neuroinflammation
In order to induce neuroinflammation, animals were subjected to surgeries by
which cannulas (Model 3280PM, Plastics One, Roanoke, VA, USA) connected to
subcutaneous osmotic mini-pumps (Model 2004, Durect Corp. Cupertino, CA, USA)
were surgically implanted into the fourth ventricle of the rat brain as described in
(Reisenauer et al. 2011). The concentration of endotoxin used in these studies (5.0
ng/hr) is based on results showing that this concentration results in significant neuroglia
activation and cholinergic cell loss above control treated rats (Reisenauer et al. 2011),
and is consistent with previous studies demonstrating a selective increase in
arachidonic acid metabolism using this model (Lee et al. 2004, Rosenberger et al.
2004). During the infusion period, rats were treated daily with either glyceryl triacetate
or water at a dose of 6 g/kg by gastric gavage using feeding tubes (Instech Solomon,
Plymouth, PA). The rats used for histone acetylation analysis were divided into four
different groups: group one (n = 8) received an aCSF infusion and were treated daily
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with water for 28 days (aCSF + H2O), group two (n = 7) received an aCSF infusion and
daily treatment with glyceryl triacetate for 28 days (aCSF + GTA), group three (n = 8)
received a LPS infusion and daily treatment with water for 28 days (LPS + H2O), and
group four (n = 5) received a LPS infusion and daily treatment with glyceryl triacetate
for 28 days (LPS + GTA). The rats used for IL-1β analysis were divided into three
different treatment groups: group one (n = 6) received an aCSF infusion (aCSF), group
two (n = 12) received a LPS infusion (LPS), and group three (n = 6) received a LPS
infusion and daily treatment with glyceryl triacetate for 28 days (LPS + GTA). On the
28th day of treatment, animals were anesthetized with isoflurane (Butler Animal Health
Supply, Dublin, OH) in an induction chamber for 1 min, and then euthanized by
decapitation. Brains were immediately removed and flash frozen by immersing in
liquid nitrogen. The post-mortem intervals for the brain did not exceed 1 min. All
samples were stored at -80º C until used. Total brain homogenate was used for histone,
HAT and HDAC isolation. Specific brain regions were not studied because the goal
was to determine if acetate had any effect on histone acetylation, HAT and HDAC
activity or expression.
Nuclei Isolation
Brain nuclei were isolated by density centrifugation as described (Kim &
Shukla 2006). Frozen brain samples were weighed and then transferred to a 50 ml
plastic centrifuge tube containing 10 ml of ice cold homogenization buffer (50mM TrisHCl, pH 6.95 containing 25mM KCl, and 10mM MgCl2 0.25M sucrose, 1mM sodium
orthovanadate, 5mM sodium fluoride, 1mM phenylmethylsulfonyl fluoride (PMSF),

23

and a protease inhibitor cocktail). The homogenized samples were gravity filtered
through 100 µM nylon mesh, then diluted with the addition of another 5 ml of
homogenization buffer. The diluted homogenate was then centrifuged at 900 x g for 30
min at 4o C. The pellet was re-suspended in homogenization buffer having a sucrose
concentration of 0.8 M sucrose brain by mixing for 30 min at 4o C. The nuclei were
isolated by density centrifugation (100,000 x g for 1.5 hr at 4o C) with the lower layer
containing homogenization buffer with 1.2 M sucrose brain. Following centrifugation,
the supernatant was discarded and the nuclear pellet was washed twice in a hypotonic
wash solution (50 mM Tris-HCl, 1 mM KCl, 1.5 mM MgCl2 6-hydrate, pH 8.0)
containing 1mM PMSF using slow intermittent mixing. Using additional samples, the
pellets were washed with ammonium sulfate NH4 (S04)2 solution (pH 5.5) instead of
hypotonic wash and the supernatant was used to compare the yield of HDAC activity as
described in Results section #2. The samples were then centrifuged again at 1,000 x g
for 20 min at 4o C, the pellet was collected and the supernatant was kept for enzymatic
activity and Western blot analysis while the pellets were used to isolate histones as
described below.
Acid Extraction of Histones
An acid histone extraction was used to isolate nuclear histones (Shechter et al.
2007). The nuclear pellets were re-suspended in 2.0 ml of 0.4 N H2SO4 and then
incubated with shaking at 4o C overnight. The samples were then centrifuged at 16,000
x g for 10 min at 4o C. The supernatant was transferred to a second test tube and the
solution was brought up to 33% trichloroacetic acid (TCA) with the addition of 1.0 ml
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100% TCA solution. The samples were incubated at 4o C for 1 hr then centrifuged at
21,000 x g for 5 min at 4o C. The pellets containing the histones were washed with 0.5
ml acetone then allowed to dry at room temperature. The pellets were re-suspended in
2.0 ml of ice cold TKM buffer containing 1 mM PMSF then re-suspended by
sonication and mixing. The solution containing the isolated histones was centrifuged
again at 12,000 x g for 5 min at 4o C and the supernatant was stored at -80o C. Protein
was measured using the Bradford method with bovine serum albumin as standard
(Bradford 1976).
Cell Cultures
Primary microglia were derived from C57BL/6 mouse brains as described
previously (Dhawan et al. 2012). Briefly, cortices were removed and trypsinized. The
trypsin was inactivated in microglial growth media (DMEM/F-12 with L-glutamine
[Invitrogen]) containing 10% heat-inactivated fetal bovine serum, 5% heat-inactivated
horse serum, and antibiotics, penicillin, streptomycin, and neomycin (Gibco,
Invitrogen, Carlsbad, CA). The tissue was triturated and plated into tissue culture
flasks. After 24 hours all media and cellular debris was replaced with fresh media.
After 7 more days, half of the media was replaced and cells were maintained as a mixed
glia culture until day 14. At 14 days in vitro, microglia were shaken from the mixed
glial culture at 200 rpm for 45 minutes and collected for use. The BV2 microglia were
obtained from Dr. Colin K. Combs (Grand Forks, ND) and maintained until used as
described previously (Rojanathammanee et al. 2011). Cells were plated in 6 welldishes and allowed to replicate till 90% confluence, (1.1 x 106 cells/dish). The purity of
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the astrocyte cell cultures was found to be 91 + 3% as determined by immunostaining
using anti-GFAP antibody (1:1000). Prior to stimulating the cells (3 hr), the media was
changed to serum-free media. Plates were divided into 4 different groups; a group
treated with 12 mM NaCl as a control group, another group treated with 12 mM sodium
acetate, a third group treated with both 6.25 ng/ml LPS and 12 mM NaCl, and a fourth
group treated with both 6.25 ng/ml LPS and 12 mM sodium acetate (n = 6 per group for
BV-2 cells and primary astrocytes, and n = 5 per group for primary microglia). The
concentration of acetate used in this study is based on studies to determine the maximal
amount of acetate that did not lead to significant cell death over a 24 hr exposure
period, compared to cells grown in serum-fee media. After a single oral gavage of
glyceryl triacetate (5.8 g/kg), brain acetate levels rise to 8 µM/g tissue at 1 hr, and then
decline to 6 and 2 µM/g tissue at 2 and 4 hr, respectively (Mathew et al. 2005).
However, the metabolically active molecule in this process is not acetate, but rather
acetyl-CoA which reaches a maximum of 5.7 µg/g brain at 30 min and remains
constant out to 4 hr in vivo (Reisenauer et al. 2011). The cellular concentration of
acetyl-CoA is controlled metabolically by acetyl-CoA synthetases 1 and 2, and not by
cellular levels of free acetate (Fujino et al. 2001, Ariyannur et al. 2010). Therefore, our
rationale for using the highest tolerable acetate concentration was not to mimic
maximal tissue concentrations of acetate but rather to maximize, over a 4 hr-period,
cellular levels of acetyl-CoA in an effort to identify metabolic and the inflammatory
pathways that are modulated downstream of the formation of acetyl-CoA. For doseresponse studies, plates were divided in 6 different groups treated with LPS in the
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following concentrations: 25, 12.5, 6.25, 3.125, 1.56, or 0 ng/ml (n = 3). After 4 hr, the
media was collected and stored at -20° C, and the cells were lysed in either TRIzol®
reagent for qrt-PCR analysis or ice cold RIPA lysis buffer (150 mM sodium chloride,
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris,
pH 8.0) for Western blot analysis and stored at -80° C until used.
Western Blot Analysis
Equal amounts of protein were prepared by boiling samples in loading buffer
composed of 95% Laemmli sample buffer and 5% 2-mercaptoethanol (Sigma, St.
Louis, MO). The separation of proteins was performed using a 10-20% Tris-HCl gel
with an electrophoresis separation of 100 volts for 2 hr. The electrophoretic transfer of
proteins onto a 0.45 µm nitrocellulose membrane was performed at 100 volts for 90
min in ice. Primary antibodies were prepared at the following concentrations in 20 mM
Tris buffer, pH 7.4 containing 150 mM NaCl and 0.05 % Tween 20 (TTBS) containing
5 % non-fat dried milk. The antibody concentration used were total histone H4
(1:1000), acetylated histone H4K5 (1:800), acetylated histone H4K8 (1:2000),
acetylated histone H4K12 (1:800), acetylated histone H4K16 (1:1000), total histone H3
(1:500), acetylated histone H3K9 (1:1000), acetylated histone H3K14 (1:1000), HDAC
1, 2, 3, 4, 5 and 7 (1:1000), acetyl-CoA synthetase (1:500), IL-1β, IL-6, TNF-α, TGFβ1, IL-4, IL-10, total p38, phosphorylated p38, total JNK, phosphorylated JNK, total
ERK1/2, phosphorylated ERK1/2, all NF-κB antibodies (1:1000), phosphorylated
cPLA2 (1:250), total cPLA2 (1:500), sPLA2 IIA (1:500), PLCβ1 (1:250), PLCγ1
(1:350), PLCδ1 (1:350), Cox-1 (1:1000) and Cox- 2 (1:1000), and α-tubulin (1:3000).
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All primary antibodies were incubated with the nitrocellulose membranes overnight at
4o C. The blots were incubated with the appropriate secondary antibody conjugated
with a horse radish peroxidase at a dilution of 1:3000 in TTBS. The blots probed with
α-tubulin antibody were conjugated with a horse radish peroxidase-linked goat antimouse IgM secondary antibody at a dilution of 1:4000 in TTBS. Protein bands were
visualized with a SuperSignal® West Pico or Femto Chemiluminescent Substrate
(Pierce, Rockford, IL) using a UVP Bioimaging System (Upland, CA). Image
capturing and analysis was performed with LabWorks™ imaging software (version 4.5,
Upland, CA). Western blot data of acetylated histones is expressed as of the ratio of
the optical density of acetylated histone residues to the optical density of total histone.
Phosphorylated MAPK p38, JNK, ERK1/2, and phosphorylated cPLA2 are normalized
to total MAPK p38, JNK, ERK1/2, and cPLA2, respectively. Western blot data of all
other proteins is expressed as the ratio of the optical density of the respective protein to
the optical density of the loading control α-tubulin.
HDAC and HAT Enzyme Activity Assays
HDAC activity was measured using the colorimetric HDAC activity assay kit
(Millipore, Billerica, MA) according to the manufacturer’s instructions. The
colorimetric HDAC assay measures the total HDAC activity in a two-step procedure
performed in a 96-well plate. In the first step, samples are incubated with the HDAC
assay substrate, allowing deacetylation of the substrate. Next, the addition of an
“Activator Solution” releases p-nitroanilide from the deacetylated substrate or standard
which is monitored by spectrophotometric analysis. Nuclear extracts were added to the
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assay buffer with HDAC substrate and mixed thoroughly. The samples were then
incubated at 37° C for 75 min. At 75 min, an aliquot of the activator solution was
added to each well, then following a 15 min room temperature incubation, the
absorbance was measured at 405 nm. Nuclear extract provided by the manufacturers
was used as a positive control and water was used as a negative control. The HAT
activity was measured using the colorimetric HAT activity assay kit (Abcam,
Cambridge, MA) according to the manufacturer’s instructions. The colorimetric HAT
activity assay depends on the acetylation of a peptide substrate by the active HAT; a
process associated with the release of the free form of co-enzyme A. Co-enzyme A
serves as an essential co-enzyme for the production of NADH which is measured using
spectrophotometric analysis upon its reaction with a soluble tetrazolium dye. Briefly,
40 µl of nuclear extract was incubated with HAT substrate I and II and NADH
generating enzyme in 2 x HAT assay buffer for 4 hr at 37° C and absorbance was
measured at 450 nm using a Labsystems Multiskan plate reader (Helsinki, Finland).
Nuclear extracts provided by the manufacturer were used as positive control and water
was used as negative control. HAT activity is expressed as the ratio of the absorbance
at 450 nm to the amount of nuclear extract as outlined by the manufacturer.
Quantitative Real-time Polymerase Chain Reaction (qrt-PCR)
Brain cortex samples (50-100 mg each) were homogenized in 1 ml TRIzol®
reagent, using a Polytron homogenizer. Homogenized samples were incubated at room
temperature for 5 min to permit dissociation of nucleoprotein complexes before adding
0.2 ml of chloroform, shaking the tubes vigorously by hand, and incubating again at
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room temperature for 3 min. The samples were then centrifuged at 12,000 x g for 10
min at 4° C. Following centrifugation, the upper clear aqueous phase containing RNA
was transferred to fresh tubes where RNA was precipitated from the aqueous phase by
mixing with 0.5 ml of isopropyl alcohol. The mix was incubated at room temperature
for 10 min then centrifuged at 12,000 x g for 10 min at 4° C. The RNA pellet was
washed once with 1 ml of 75 % ethanol and centrifuged at 7,500 x g for 5 min at 4° C.
At the end of the RNA extraction, ethanol was decanted and the RNA pellet was
allowed to air-dry at room temperature for 5 min before re-dissolving in 200 µl of
nuclease-free water. One µg of RNA per sample was used for cDNA synthesis using
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer’s
instructions. Amplification was performed using 500 ng cDNA, 500 nM of each of the
reverse and forward primers, and FastStart Universal SYBR Green Master (Roche
Applied Science, Indianapolis, IN) in a final reaction volume of 50 µl, using a two-step
cycling program of 1 cycle of 95° C for 10 min followed by 40 repeats of 95° C for 15
sec and 60° C for 60 sec in iCycler iQ Multicolor Real-Time PCR Detection System
(Bio-Rad, Hercules, CA). The expression of all transcripts amplified was normalized
to the expression of β-actin. PCR quantification was performed using the Livak
formula 2-∆∆Ct (Livak & Schmittgen 2001). The amplicon was mixed with DNA gel
loading buffer 10 x (5 Prime, Gaithersburg, MD), and run on 1 % agarose gel at 100
volts for 1 hr. TrackIt™ DNA ladder (Invitrogen, Grand Island, NY) was used.
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Quantitative Real-time Polymerase Chain Reaction (qrt-PCR) Array
Brain cortex samples (50-100 mg each) were used for mRNA extraction, cDNA
synthesis and amplification as described in detail in the previous section. The RT²
Profiler™ PCR Array PARN 052 (SABiosceinces) has built-in primers in the 96-well
plate, and was used according to the manufacturer’s instructions. Data analysis was
performed using the SABiosceinces website data analysis tool.
Lactate Dehydrogenase Assay
Cellular release of lactate dehydrogenase (LDH) used to measure cell viability
was measured using a commercial nonradioactive assay kit (Clontech Inc.), according
to the manufacturer’s guidelines. Absorbance measurements were taken at 490 nm.
Chromatin Immunoprecipitation
After treating the BV-2 cells for 4 hr, cross linking was done using 1%
paraformaldehyde at room temperature for 10 min, then stopped by 0.125 M glycine at
room temperature for 5 min. The cells were then washed once with phosphate-buffered
saline ((PBS) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, and pH
7.4) before adding 0.2% trypsin and incubating at 37° C for 5 min in 5% carbon
dioxide. Trypsin was neutralized by twice the volume of fetal bovine serum. One
million cells per chromatin immunoprecipitation per antibody were suspended in SDS
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) containing protease
inhibitor cocktail and sonicated for 7 cycles of 12 pulses with 3-sec intervals on ice
between cycles. The sonicated cells were centrifuged at 15000 g to remove the debris
out of the lysates. Seven µg of acetylated H3K9 antibody and normal rabbit IgG,
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protein A and protein G magnetic beads were used for immunoprecipitation for 3 hr at
4° C. The magnetic beads were washed 4 times with low-salt wash buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), once with
high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl,
pH 8.1, 500 mM NaCl), and once with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH
8.0). The samples were then eluted at 65° C for 15 min using elution buffer (50 mM
Tris-HCl, 10 mM EDTA, 1% SDS, pH 8.0). Samples were incubated at 65° C
overnight to reverse the crosslinks, then incubated with RNAse A (0.2 µg/ml) for 2 hr
at 37° C, and with proteinase K (0.2 µg/ml) for 2 hr at 55° C. One µg of the Chromatin
immunoprecipitation end product, with 1 µg of forward and reverse primers, 10 µl
SYBR green, and 8 µl of nuclease-free water were used for quantitative real-time
polymerase chain reaction (qrt-PCR).
Prostaglandin E2 Quantification using Enzyme Immunoassay
PGE2 release was measured in the media of BV-2 microglia and primary
astrocyte cell cultures using prostaglandin screening enzyme immunoassay (EIA) kit
according the manufacturer’s instructions. The test depends on the competition
between PGs and PG-acetyl choline esterase conjugate for a limited amount on PG
antiserum. Absorbance was read at 405 nm.
Statistical Analysis
To compare between more than two groups, parametric or nonparametric One
Way Analysis of Variance (ANOVA) was used when appropriate, followed by Tukey’s
or Dunn’s post-hoc test, respectively. When comparison was made between only two
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groups, two-tailed unpaired t-test was used to calculate statistical differences using
GraphPad InStat statistical software (Version 3.10, San Diego, CA). All results are
expressed as means ± SD and significance was set at p < 0.05. Figures were prepared
using SigmaPlot for Windows, version 10.0, Build 10.0.1.25.
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CHAPTER III
RESULTS
Method Optimization for Western Blot Analysis
Saturation of the Western blot image occurs when too much protein is loaded or
as a result of increasing the exposure time of the Western blot during
chemiluminescence detection using the imaging system. To demonstrate that, the
same Western blot was probed for the loading control histone H4 (primary antibody
concentration 1:1000) and exposed during chemiluminescence detection for 5 min
(Figure 1A) and 30 sec (Figure 1B). The analysis of the blot in Figure 1A using
Visionwoks® software demonstrated a flat-topped peak with maximum intensity of
around 3000 (Figure 1C). The analysis of the blot in Figure 1B using Visionwoks®
software demonstrated a pointed peak with maximum intensity of around 2500 (Figure
1D). That is, the intensity of the peak in Figure 1C was 1.2 times greater than that of
Figure 1D even though the exposure time of the blot in figure 1A was 10 times that of
the blot in figure 1B. Therefore, the increase in exposure time during
chemiluminescence detection was not matched by an equal increase in the intensity of
the optical density indicating saturation which prevents accurate quantification of
protein based on the optical density. In the light of that, before embarking on Western
blot analysis for the histone acetylation studies, we performed experiments to optimize
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the protein amount and exposure duration during chemiluminescent detection to avoid
saturation with Western blot analysis.
Optimizing the amount of protein for Western blot analysis.
In order to determine the optimal amount of protein to use for Western blot
analysis, we loaded a serial dilution of histone extract (41-0.08 µg/lane), probed for the
loading control histone H4 (1:1000), and exposed the blot for 2 min (Figure 2A). We
found that optical density leveled off with protein amounts greater than 3 µg/lane
(Figure 2B). These data demonstrate that the linear range of protein amount under
(A)

these experimental conditions is 1-3 µg (Figure 3C). The correlation coefficient is
close to 1 (r2 = 0.993), which means that the amount of protein can be quantified based
on the optical density without saturation because increasing the protein load within this
range is matched by proportionate increases in intensity of optical density.
(A)

(B)

Figure 1. Demonstration of saturation in Western blot analysis.
Images obtained by Visionworks® software of the loading control histone H4
(primary antibody concentration 1:1000) representing the intensity of the optical
density on the y-axis. Panel (A) demonstrates a saturated Western blot image exposed
during chemiluminescence detection for 5 min. Panel (B) demonstrates the same
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Western blot image after 30 sec of exposure. Panel (C) shows the optical density
analysis of the image in panel (A) using Visionworks® software and demonstrates
saturation. Panel (D) demonstrates the optical density analysis of image in panel (B)
and represents a quantifiable image with no saturation.

Figure 2. Demonstration of the quantifiable range of protein content for Western blot
analysis.
Optical density was plotted on the y-axis versus protein (µg) on the x-axis.
Panel (A) shows the Western blot image of the serial dilution of histone extract (41-0.08
µg/lane), probed for with anti-histone H4 (1:1000), and exposed during
chemiluminescence detection for 2 min. Panel (B) represents the quantification of the
optical density of the protein concentrations (41-0.08 µg/lane) and demonstrates leveling
off of the optical dentistry with protein amounts greater than 3 µg/lane. Panel (C)
demonstrates the linear range of protein (1-3 µg/lane) prepared to represent a
quantifiable range of protein. Blotting histone in this range allows the quantification of
histone acetylation state based on the optical density without saturation.
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Optimizing the duration of exposure during chemiluminescene detection
for Western blot analysis.
Because saturation develops with increasing the exposure time during the
chemiluminescence detection, we proceeded to determine the optimal duration for
Western blot exposure. A Western blot analysis was performed with loading histone
extract (3 µg), probing for the loading control histone H4 (1:1000), and the blot was
exposed for a range of durations between 15 sec and 30 min (Figure 3A). The optical
density increased with increasing the exposure time from 15 sec to 4 min before
leveling off (Figure 3A and B). These data demonstrate that the linear range for
Western blot exposure under these experimental conditions is between 15 sec and 4
min. The correlation coefficient is close to 1 (r2 = 0.998), which means that increasing
the Western blot exposure within this range is matched by proportionate increases in
optical density without saturation.

Figure 3. Demonstration of the optimal exposure duration for Western blot during the
chemiluminescence detection.
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The optical density is plotted on the y-axis verses the exposure time (min) on
the x-axis. Panel (A) shows leveling off of the optical density with exposure for more
than 4 min. Panel (B) shows the linear part of the curve from 30 sec to 4 min.
The rationale for using histone extract for these optimization studies is that it is
purer and more concentrated than whole cell lysates and brain homogenates.
Therefore, saturating amounts of protein in histone extract are unlikely to be saturating
when used to probe for less concentrated targets; for example, MAPK p38 or cPLA2 in
using whole cell lysates or brain homogenate. Likewise, the antibody against total
histone H4 detects all acetylated and non-acetylated histones H4, and therefore
saturating protein amounts detected by total histone H4 antibody are unlikely to be
saturating when probing for the acetylated histones. For Western blot analyses other
than histone acetylation studies, we avoided saturation by capturing the images of each
blot at several exposure times and depended on the shape of the peak on the image
generated by Visionworks® software to exclude saturation.
Determining the Distribution of HDAC Activity in Different Cellular Fractions
We measured the levels of HDAC activity in the different cellular
fractions obtained during the procedures of nuclei isolations. In addition to washing the
nuclear pellet with hypotonic wash, we used additional samples to wash the nuclear
pellet with NH4 (S04)2 solution to compare the HDAC activity yielded by the two
methods (Method section under “nuclei isolation”). We found that each of the
hypotonic wash 1 and 2 had 2-3 times more HDAC activity than any of the other

38

fractions including the cytosol (Figure 4). Therefore, hypotonic wash 1 and 2 were
combined and used for measuring the enzymatic activities of HAT and HDAC.

Figure 4. Comparison between the levels of HDAC activity in the cellular fractions
obtained during the procedure of isolation of nuclei and with NH4 (S04)2 wash.
Hypotonic wash 1 and 2 had considerably higher HDAC activity than the other
fractions and the NH4 (S04)2 wash, so they were used for the measurement of HAT and
HDAC enzymatic activities. The composition of the hypotonic washes, sucrose
gradient and NH4 (S04)2 are described in the Method section under “Nuclei isolation”.
A Single Oral Dose of Acetate Supplementation and Brain Histone Acetylation in
Normal Rats
The proportion of acetylated H3 and H4 to total histone was measured at
differing time points following a single oral gavage with glyceryl triacetate (6 g/kg)
using Western blot analysis. Specific antibodies against acetylated histones H4K5,
H4K8, H4K12, H4K16, H3K9, and H3K14 as well as specific antibodies towards total
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histone H3 and total histone H4 were used to measure brain histone acetylation state.
Total histone H3, H3K9, and H3K14 were detected as protein bands at 17 kDa which
correspond to the molecular weight of these types of histones (Figure 5A). Similarly,
H4K5, H4K8, H4K12, H4K16 and total histone H4 were detected as protein bands at
10 kDa which correspond to the molecular weight of these types of histones. Optical
density analysis of the Western blots showed that acetate supplementation significantly
increased the acetylation state of brain histone H3K9 by 1.5-fold at 4 hr following
treatment compared to controls (Figure 5B). No changes in the acetylation of brain
histone H3K14 were detected at any of the time points examined (Figure 5C). Optical
density analysis of acetylated histone H4 showed that the acetylation state of brain
histone H4K8 was increased 1.7-fold at 2 and 4 hr and brain histone H4K16 was
increased 1.7- and 1.8-fold at 4 and 24 hr following treatment (Figure 5E and G).
Acetate supplementation did not change the acetylation state of brain histone H4K5 and
H4K12 at any of the time points examined (Figure 5D and F). These data suggest that
a single oral dose of acetate treatment can induce site- and time-specific histone
acetylation changes.
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Figure 5. A single oral dose of acetate supplementation and brain histone acetylation in
normal rats.
The effect of a single oral dose of acetate supplementation on the histone
acetylation state of brain histones H3K9, H4K8, and H4K16 at 0.5, 1, 2, 4 and 24 h
following treatment with 6 g/kg glyceryl triacetate (GTA). Panel A shows
representative images of the Western blots while panels B-G show the quantification of
the optical densities of acetylated histone. The different panels represent the
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acetylation ratio of H3K9, H3K14, H4K5, H4K8, H4K12 and H4K16 normalized to
total H3 or total H4, respectively. Bars represent the means ± SD of optical density
analysis where statistical significance (*) was set at p < 0.05 as determined by One
Way ANOVA followed by Tukey’s post-hoc test (n = 6 animals per group).
A Single Oral Dose of Acetate Supplementation and Brain HDAC and HAT
Activity
Having observed an increase in brain histone H3 and H4 acetylation state
following acetate supplementation, we proceeded to determine the effect that a single
oral dose of glyceryl triacetate has on the temporal activity of brain HDAC and HAT.
Using commercially available HDAC and HAT assay kits, we observed a significant
2.3- and 2.8-fold decrease in the brain HDAC activity at 2 and 4 hr following treatment,
respectively (Figure 6A). The HDAC activity in the control sample was 0.198 + 0.06
mM/75 min/μg protein while the HDAC activities at 2 and 4 hr were 0.085 + 0.03 and
0.07 + 0.02 mM/75 min/μg protein, respectively. In parallel experiments, we did not
observe significant changes in brain HAT activity at any of the time points examined
when compared to controls (Figure 6B).
A Single Oral Dose of Acetate Supplementation and Brain HDAC Expression
HDAC enzymes are classified into three different classes (de Ruijter et al.
2003). Class I (1, 2, 3, and 8) and class II (4, 5, 6, 7, and 9) are localized in the nucleus
or shuttle between the cytoplasm and the nucleus following stimulation, respectively.
Class III, the sirtuins, found primarily in the cytoplasm and mitochondria are inhibited
by nicotinamide unlike conventional HDAC inhibitors (Avalos et al. 2005, Sanders et
al. 2007). Therefore, based on the nuclear localization and to explain the decrease in
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nuclear HDAC activity, we measured the expression of class I and II HDAC using
Western blot analysis. Specific antibodies against HDAC1, 2, 3, 4, 5 and 7 were used
to measure brain HDAC expression levels as compared to control animals. The
proportion of HDAC to α-tubulin was calculated at 4 hr following a single oral gavage
with glyceryl triacetate (6 g/kg) (Figure 7A).

Figure 6. A single oral dose of acetate supplementation and brain HDAC and HAT
activity.
The effect of a single oral dose of acetate supplementation on histone
deacetylases (HDAC, panel A) and histone acyltransferases (HAT, panel B) activity in
different rat groups euthanized at 0.5, 1, 2, 4, and 24 h following treatment with 6 g/kg
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glyceryl triacetate (GTA). Panel C shows the standard curve for colorimetric HDAC
assay. The linear part of the curve lies between standard concentrations 1 mM and
0.016 mM and the absorbance value is read at 405 nm. Panel D shows the standard
curve for colorimetric HAT assay set up using different dilutions of the sample with the
highest protein concentration. The graph shows steady increase in the absorbance at
450 nm with increasing the protein content from 1.5 to 4 μg. All our samples fell
within this range. Bars represent the means ± SD of absorbance reading at 405 nm
after 75 min of incubation at 37° C normalized to the protein assayed (µg). Statistical
significance (*) was set at p < 0.05 as determined by One Way ANOVA followed by
Tukey’s post-hoc test (n = 6 animals per group).
The analysis detected protein bands at 62, 60, 49, 140, 124, 105 and 50 kDa
corresponding to the molecular weights of HDAC1, 2, 3, 4, 5, 7 and α-tubulin,
respectively (Figure 7A). Optical density analysis of these Western blots showed that
acetate significantly decreased brain HDAC2 levels by 50% below control values at 4
hr following treatment (Figure 7B). Acetate supplementation did not decrease the
expression of the other brain HDAC measured. These results suggest that the increase
in histone acetylation following acetate supplementation may be due to a decrease in
the protein levels of HDAC2.
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Figure 7. A single oral dose of acetate supplementation and brain HDAC expression.
The effect of a single oral dose of acetate supplementation on the brain HDAC2
levels at 4hr, in control and glyceryl triacetate (GTA)-treated rats. Figure 7A shows
representative images of Western blots of HDAC2 and α-tubulin. Figure 7B shows the
ratio of brain HDAC2 normalized to α-tubulin. Bars represent the means + SD of
optical density analysis where statistical significance (*) was set at p < 0.05 as
determined using a two-tailed unpaired t-test (n = 6 animals per group).
Long-term Acetate Supplementation and Brain Histone H3 and Histone H4
Acetylation in a Rat Model of Neuroinflammation
The proportions of acetylated histone H3 and H4 were measured using Western
blot analysis. Total H3, acetylated H3K9, and acetylated H3K14 were detected as
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protein bands corresponding to a molecular weight of 17 kDa (Figure 8A). Optical
density analysis of acetylated H3 showed a 1.6-fold increase in the proportion of H3K9
in the two groups of rats subjected to acetate supplementation (aCSF + GTA) and (LPS
+ GTA), compared to controls (aCSF + H2O) (Figure 8B). Interestingly, the proportion
of acetylated H3K9 was decreased by 2-fold in rats subjected to neuroinflammation and
treated with water (LPS + H2O) and 3-fold when compared to rats that received acetate
(aCSF + GTA) and (LPS + GTA). Neither acetate supplementation nor
neuroinflammation altered the acetylation state of brain H3K14.
Total H4 and acetylated H4K5, H4K8, H4K12, and H4K16 were detected as a
protein bands at 10 kDa which correspond to the molecular weight of these histones
(Figure 9A). Similar to the proportional increases in acetylated H3K9, the proportions
of acetylated H4K8 and H4K16 were significantly increased by 2-fold in rats subjected
to acetate supplementation (aCSF + GTA) and (LPS + GTA) (Figure 9B). However,
unlike the proportion of acetylated H3K9, the proportion of acetylated H4K8 and
H4K16 were not decreased in the rats subjected to neuroinflammation and treated with
water (LPS + H2O) when compared to controls (aCSF + H2O). Neither acetate
supplementation nor neuroinflammation altered the acetylation state of H4K5 or
H4K12. These results suggest that acetate supplementation can selectively and
positively regulate the acetylation of both histone H3 and H4 at specific acetylation
sites. However, LPS-induced neuroinflammation only decreased the acetylation state
of H3K9, which was effectively reversed with acetate supplementation.
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Figure 8. Long-term acetate supplementation and brain histone H3 acetylation in a rat
model of neuroinflammation.
.
Changes in the acetylation state of brain H3K9, and H3K14 in control rats
(aCSF), rats subjected to neuroinflammation (LPS), and rats treated with either water
(H2O) or glyceryl triacetate (GTA). Panel A shows representative images of the
Western blots, and panel B shows the averaged proportion of brain H3K9 and H3K14,
normalized to total H3. The data represent the means ± SD where statistical
significance (a = compared to aCSF + H2O, and b = compared to LPS + H2O) was set
at p < 0.05, as determined by One Way ANOVA followed by Tukey’s post-hoc test.
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Figure 9. Long-term acetate supplementation and brain histone H4 acetylation in a rat
model of neuroinflammation.
Changes in the acetylation state of brain H4K5, H4K8, H4K12, and H4K16 in
control rats (aCSF) and rats subjected to neuroinflammation (LPS), and rats treated
with either water (H2O) or glyceryl triacetate (GTA). Panel A shows representative
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images of the Western blots, while panel B shows the averaged proportion of brain
H4K5, H4K8, H4K12, andH4K16, normalized to total H4. The data represent the
means ± SD where statistical significance (a = compared to aCSF + H2O, and b =
compared to LPS + H2O) was set at p < 0.05, as determined by One Way ANOVA
followed by Tukey’s post-hoc test.
Long-term Acetate Supplementation and Brain HDAC and HAT Activities in a
Rat Model of Neuroinflammation
Because the brain histone acetylation state is controlled by the activities of HAT
and HDAC, we examined the effect that acetate supplementation had on brain HAT and
HDAC activities in different test groups. Using commercially available HDAC and
HAT assay kits, we found that acetate supplementation significantly increased by 1.8and 1.6-fold the activity of brain HAT in (aCSF + GTA) and (LPS + GTA) groups,
respectively, compared to controls (aCSF + H2O) (Figure 10). No changes in HAT
activity were observed in rats subjected to neuroinflammation and treated with water
(LPS + H2O). The HAT activity in the control sample was 35 ± 12 absorbance units at
450 nm/µg protein, while the HAT activities in the (aCSF + GTA) and the (LPS +
GTA) groups were 62 ± 14 and 56 ± 10 absorbance units at 450 nm/µg protein,
respectively. In parallel experiments, we did not find any changes in brain HDAC
activity in any of the groups tested. These results suggest that long-term acetate
supplementation, and not LPS-induced neuroinflammation, positively regulates brain
HAT activity with no apparent effect on brain HDAC activity.
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(A)

(B)

Figure 10. Long-term acetate supplementation and brain HDAC and HAT activities in a
rat model of neuroinflammation.
The effect of long-term acetate supplementation on brain HAT and HDAC
activities in control rats (aCSF) and rats subjected to neuroinflammation (LPS), and rats
treated with either water (H2O) or glyceryl triacetate (GTA). Panel (A) represents
changes in brain histone acyltransferases (HAT), and panel (B) represents changes in
histone deacetylases (HDAC) activities. HAT enzyme activity is expressed as the
means ± SD of absorbance reading at 450 nm after 4 hr of incubation at 37° C,
normalized to the protein assayed (µg). HDAC enzyme activity is expressed as the
means ± SD of absorbance at 405 nm after 75 min of incubation at 37° C, normalized to
the protein assayed (µg). Statistical significance (* = compared to aCSF + H2O
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controls) was set at p < 0.05, as determined by nonparametric One Way ANOVA
followed by Dunn’s post-hoc test.
Long-term Acetate Supplementation and Brain HDAC Expression in a Rat Model
of Neuroinflammation
We found earlier that a single oral dose of glyceryl triacetate decreases HDAC
activity and reduces the expression of HDAC2 (Soliman & Rosenberger 2011). We did
not observe changes in HDAC activity suggesting that the effects of long-term
treatment differ substantially from a single oral dose. In order to further understand the
effect that long-term acetate supplementation has on HDAC expression, we measured
changes in the individual HDAC levels using Western blot analysis. Optical density
analysis showed that HDAC1 expression was significantly elevated by 2.4- and 1.7fold in rats treated with glyceryl triacetate; (aCSF + GTA) and (LPS + GTA) (Figure
11B). A similar effect was found in HDAC2 expression where the level was
significantly increased by 1.7-fold in rats treated with acetate (aCSF + GTA), but not in
rats subjected to neuroinflammation (LPS + GTA). The expression levels of HDAC1
and HDAC2 were not altered by LPS-induced neuroinflammation treated with water
(LPS + H2O). On the contrary, the levels of HDAC3 were significantly decreased by
40% in rats treated with acetate; (aCSF + GTA) and (LPS + GTA) as compared to
control rats (aCSF + H2O). The HDAC3 expression level was not altered in rats
subjected to neuroinflammation treated with water (LPS + H2O) as compared to control
rats (aCSF + H2O). Most interestingly, the expression of HDAC7 was increased by
1.7-fold in rats subjected to neuroinflammation and treated with water (LPS + H2O)
which was effectively reversed with acetate supplementation (aCSF + GTA) and (LPS
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+ GTA). No changes were found in the expression levels of HDAC4 and 5 in any of
the groups tested. These results suggest the HDAC7 may play a positive role in the
inflammatory process evoked by long-term LPS infusion that does respond to longterm acetate supplementation.

(A)

(B)

Figure 11. Long-term acetate supplementation and brain HDAC expression in a rat
model of neuroinflammation.
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The effect of long-term acetate supplementation on the expression of individual
brain HDAC in control rats (aCSF) and rats subjected to neuroinflammation (LPS), and
rats treated with either water (H2O) or glyceryl triacetate (GTA). Panel A shows
representative images of the Western blots, while panel B shows the quantifications of
HDAC1, 2, 3, 4, 5 and 7. Data in panel B represent means ± SD of the optical densities
of HDAC1, 2, 3, 4, 5 & 7, normalized to α-tubulin. Statistical significance (* =
compared to aCSF + H2O controls) was set at p < 0.05, as determined by One Way
ANOVA followed by Tukey’s post-hoc test for HDAC2, 3, 4 & 5, and nonparametric
One Way ANOVA followed by Dunn’s post-hoc test for HDAC1 & 7.
Long-term Acetate Supplementation and Brain IL-1β Expression in a Rat Model
of Neuroinflammation
To test whether acetate supplementation can reduce the expression of proinflammatory cytokines in vivo, and to provide insight into the anti-inflammatory
mechanism by which acetate supplementation is effective in this model of
neuroinflammation, we measured the effect that acetate treatment has on the protein
and mRNA levels of brain pro-inflammatory cytokine IL-1β. In these experiments, we
found protein bands corresponding to a molecular weight of 17 kDa corresponding to
IL-1β (Figure 12A), and cDNA bands corresponding to 209 and 131 base pairs which
correspond to the expected base pair size of IL-1β and β-actin, respectively (Figure
12C). In rats subjected to neuroinflammation (LPS + H2O), IL-1β protein and mRNA
levels were significantly elevated by 1.3- and 10-fold, respectively, (Figure 12B and
D). Further, the long-term acetate supplementation significantly reduced the expression
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level of IL-1β below that found in rats subjected to neuroinflammation (LPS), and
equal to the control levels (aCSF).

Figure 12. Long-term acetate supplementation and brain IL-1β expression in a rat
model of neuroinflammation.
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The effect of long-term acetate supplementation on the expression of brain IL1β in control rats (aCSF) and rats subjected to neuroinflammation (LPS), and rats
treated with either water (H2O) or glyceryl triacetate (GTA) as determined by Western
blot analysis and quantitative real-time PCR. Panel A shows Western blot
representative images of bands for IL-1β and -tubulin and panel B shows the means ±
SD of the normalized optical density of IL-1β protein. Panel C shows representative
images of the bands for IL-1β and β-actin cDNA and panel D shows the means ± SD of
the normalized amplified IL-1β cDNA. Statistical significance (a = compared to aCSF
+ H2O, and b = compared to LPS + H2O) was set at p < 0.05 (n = 6, per group), as
determined by One Way ANOVA followed by Tukey’s post-hoc test.
Optimizing the Duration of Acetate Treatment and LPS Concentration in BV-2
Microglia
In rat brain, H3K9 acetylation is reduced by 50% in a model of
neuroinflammation and is returned to control levels with acetate supplementation. To
determine the duration of acetate treatment required to achieve a similar H3K9
hyperacetylation pattern in vitro, we treated BV-2 microglia with 12 mM sodium
acetate for 1, 2 and 4 hr (Figures 13A and B). Cell lysates were used for Western blot
analysis to measure acetylated H3K9, total histone H3 (Figure 13A). We found that
acetate treatment increased H3K9 acetylation by 2 hr which remained elevated out to 4
hr (Figure 13B). To insure protein expression following treatment, we used 4 hr as the
treatment duration for all the experiments with the exception of change in MAPK
phosphorylation where additional time points were used. To determine the optimal
LPS concentration required to produce the same percentage of H3K9 hypoacetylation
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found in vivo, we treated BV-2 microglia for 4 hr using a serial dilution of LPS ranging
between 0 and 25 ng/ml (Figures 13C and D-G). Cell lysates were used for Western
blot analysis to measure acetylated H3K9, total histone H3 and the pro-inflammatory
cytokines pro-IL-1β, IL-6, and TNF-α, which were detected as protein bands
corresponding to the molecular weights of 17, 17, 32, 25 and 23, respectively (Figure
13C). LPS reduced H3K9 acetylation and increased the pro-inflammatory cytokine
levels in a concentration-dependent manner (Figures 13D-G). Based on these data, we
used the LPS concentration 6.25 ng/ml because this concentration resulted in a 50%
reduction in H3K9 acetylation, similar to that found in vivo (Soliman et al. 2012b), and
also increased protein levels of all the pro-inflammatory cytokines measured.
In figure 13 below, time-dependent acetate-induced H3K9 hyperacetylation and
dose-response study showing the effects of different LPS concentrations (0-25 ng/ml, 4
hr) on H3K9 acetylation and the expression of pro-inflammatory cytokines in BV-2
microglia. Panels A and C show representative images of the Western blots. Panel B
shows the averaged proportion of H3K9 normalized to total H3 (n = 3) after 1, 2 and 4
hr of treatment with 12 mM sodium acetate. Panels D, E, F and G show the optical
densities of H3K9 normalized to total H3 and the pro-inflammatory cytokines pro-IL1β, IL-6, and TNF-α normalized to the loading control α-tubulin (n = 3). The graphs
represent the means ± SD where statistical significance (* = compared to control in
panel B and compared to LPS 0 ng/ml in panels D-G) was set at p < 0.05, as
determined by One Way ANOVA followed by Tukey’s post-hoc test.
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Figure 13. Optimizing the duration of acetate treatment and LPS concentration in BV-2
microglia.
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Acetate Treatment Reverses LPS-induced H3K9 Hypoacetylation without
Inducing Cytotoxicity in Primary Microglia
To determine the ability of acetate treatment to reverse LPS-induced H3K9
hypoacetylation in microglia similar to that found in the rat (Soliman et al. 2012b), we
treated primary mouse microglia with LPS 6.25 ng/ml for 4 hr in the presence and
absence of 12 mM sodium acetate, with 12 mM NaCl treatment as control. Using
whole cell lysates for Western blot analysis, we found that primary microglia express
the enzyme acetyl-CoA synthetase which converts acetate to acetyl-CoA, as protein
bands corresponding to the molecular weight of 79 kDa (Figure 14A). The expression
level of ACS was not different between groups (Figure 14B). Further, acetate
treatment increased H3K9 acetylation by 1.7-fold, whereas LPS reduced H3K9
acetylation by 50% (Figure 14C). Acetate treatment, similar to that found in vivo,
effectively increased H3K9 acetylation to control levels in the presence of LPS (Figure
14C). Cell viability assays showed no difference in cell survival between groups
(Figure 14D). These data indicate that acetate treatment in vitro reverses LPS-induced
H3K9 hypoacetylation in microglia similar to that found in vivo (Soliman et al. 2012b).
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Figure 14. Acetate treatment and H3K9 acetylation in LPS-stimulated primary
microglia.
Changes in histone acetylation in primary mouse microglial cell culture
stimulated for 4 hr with LPS 6.25 ng/ml, and the reversal of these effects upon
treatment with 12 mM sodium acetate. Panel A shows representative images of the
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Western blots. Panels B and C show the optical densities of acetyl-CoA synthetase
enzyme normalized to the loading control α-tubulin (n = 3) and H3K9 normalized to
total H3 (n = 5), respectively. Panel D shows the quantification of the ratio of secreted
LDH in the media to total cellular LDH (n = 5). Bars represent means + SD where
statistical significance (a = compared to NaCl, and b = compared to LPS) was set at p ≤
0.05, as determined by a one way ANOVA followed by Tukey’s post-hoc test.
Acetate Treatment Reverses LPS-induced Increases in the Pro-inflammatory
Cytokine Proteins, but not mRNA, in Primary Microglia
To determine the ability of acetate treatment to reverse pro-inflammatory
cytokine production in vitro similar to that found in vivo (Soliman et al. 2012b), cell
lysates were analyzed using Western blot to probe for IL-1β, IL-6 and TNF-α (Figure
15A). We found that LPS increased pro-IL-1β, IL-6 and TNF-α by about 4, 1.5 and
2.5-fold, respectively which were returned to control levels with acetate treatment
(Figures 15B, D and F). In parallel studies, we found that LPS increased the mRNA
levels of all the pro-inflammatory cytokines measured but were not altered by acetate
treatment (Figures 15C and G) with the exception of IL-6 mRNA which was attenuated
3-fold (Figure 15E). These data demonstrate that this in vitro system reproduces the
findings from the animal model, and that acetate treatment decreases pro-inflammatory
cytokine levels possibly by disrupting mRNA translation or by increasing protein
turnover.
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Figure 15. Acetate treatment and the expression of pro-inflammatory cytokines in LPSstimulated primary microglia.
Changes in the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in primary
mouse microglial cell culture stimulated for 4 hr with LPS 6.25 ng/ml with and without
12 mM sodium acetate. Panel A shows representative images of the Western blots.
Panels B, D and F show the optical densities of the pro-inflammatory cytokines pro-IL1β, IL-6 and TNF-α, respectively, normalized to the loading control α-tubulin (n = 5).
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Panels C, E and G show the changes in the mRNA levels of the pro-inflammatory
cytokines IL-1β, IL-6 and TNF-α, quantified by qrt-PCR and normalized to β-actin (n =
5). Bars represent means + SD where statistical significance (a = compared to NaCl,
and b = compared to LPS) was set at p ≤ 0.05, as determined by a one way ANOVA
followed by Tukey’s post-hoc test.
Acetate Treatment Reverses LPS-induced H3K9 Hypoacetylation in BV-2
Microglia without Inducing Cell Death
We examined H3K9 acetylation in BV-2 microglia (Figure 16A) under the
same experimental conditions used with primary mouse microglia to confirm that both
cell types respond similarly. First, we confirmed that BV-2 microglia express acetylCoA synthetase; which was not different between groups (Figure 16B). Further, we
found that acetate treatment increased H3K9 acetylation by 1.8-fold, and reversed the
LPS-induced 50% reduction in H3K9 acetylation (Figure 16C) similar to that found in
primary microglia cultures. Further, like the primary microglia cultures, treatment did
not alter cell viability (Figure 16D).
Acetate Treatment Reverses the LPS-induced Increases in Pro-inflammatory
Cytokine Protein, but not mRNA, in BV-2 Microglia
We proceeded to determine the effect of acetate treatment and LPS on proinflammatory cytokine proteins (Figure 17A) and mRNA levels in BV-2 microglia
under the same experimental conditions used with primary microglia to confirm that
both cell types respond similarly in this regard. We found that LPS increased pro-IL1β, IL-6 and TNF-α production by 25-, 1.5-, and 8-fold respectively which were
returned to control levels with acetate treatment (Figures 17B, D, and F).
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Figure 16. Acetate treatment and H3K9 acetylation in LPS-stimulated BV-2 microglia.
Changes in histone acetylation in BV-2 microglial cell culture stimulated for 4
hr with LPS 6.25 ng/ml, and the reversal of these effects upon treatment with 12 mM
sodium acetate. Panel A shows representative images of the Western blots. Panels B
and C show the optical densities of acetyl-CoA synthetase enzyme normalized to the
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loading control α-tubulin and H3K9 normalized to total H3, respectively (n = 6). Panel
D shows the quantification of the ratio of secreted LDH in the media to total cellular
LDH (n = 6). Bars represent means + SD where statistical significance (a = compared
to NaCl, and b = compared to LPS) was set at p ≤ 0.05 (n = 6, per group), as
determined by a one way ANOVA followed by Tukey’s post-hoc test.
In parallel, we found that LPS increased the mRNA levels of the same proinflammatory cytokines similar to that found with the primary microglia cultures and
were not altered by acetate treatment (Figures 17C and G) with the exception of IL-6
which was attenuated 2-fold (Figure 17E). Therefore, the inflammatory response of
BV-2 microglia towards LPS and acetate treatment is similar to that of primary
microglia.
Acetate Treatment Increases the Expression of Anti-inflammatory Cytokines in
BV-2 Microglia
Anti-inflammatory cytokines are an integral part of the inflammatory response
to minimize the potential of the pro-inflammatory cytokines to produce neuronal
damage. We determined the effect of acetate treatment on expression levels of the antiinflammatory cytokine proteins TGF-β1, IL-4, and IL-10 (Figure 18A). Acetate
treatment did not alter the protein levels of TGF-β1 or IL-10 (Figures 18B and F);
however, IL-4 was increased by 1.3-fold (Figure 18D). In parallel, we found that
acetate treatment increased TGF-β1 mRNA by 2-fold (Figure 18C) and IL-4 mRNA by
11- and 4-fold, depending on the group (Figure 18E). Conversely, LPS increased IL-10
protein and mRNA by 1.4- and 16-fold, respectively. Acetate treatment returned IL-10
protein to control levels and attenuated IL-10 mRNA by 8-fold (Figures 18F and G).
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The possible reasons why increases in mRNA levels are not paralleled by increased
protein levels may involve mRNA stability or reflect the short treatment duration.
Regardless, these data suggest that acetate treatment modulates pro- and antiinflammatory cytokine release in BV-2 microglia towards a more anti-inflammatory
state.

Figure 17. Acetate treatment and the expression of pro-inflammatory cytokines in LPSstimulated BV-2 microglia.
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Changes in the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in BV-2
microglial cell culture stimulated for 4 hr with LPS 6.25 ng/ml with and without 12
mM sodium acetate. Panel A shows representative images of the Western blots. Panels
B, D and F show the optical densities of the pro-inflammatory cytokines pro-IL-1β, IL6 and TNF-α, respectively, normalized to the loading control α-tubulin. Panels C, E
and G show the changes in the mRNA levels of the pro-inflammatory cytokines IL-1β,
IL-6 and TNF-α, quantified by qrt-PCR and normalized to β-actin. Bars represent
means ± SD where statistical significance (a = compared to NaCl, and b = compared to
LPS) was set at p ≤ 0.05 (n = 6, except pro-IL-1β where n = 5), as determined by a one
way ANOVA followed by Tukey’s post-hoc test.
In Figure 18 below, changes in the anti-inflammatory cytokines TGF-β1, IL-4,
and IL-10 in BV-2 microglial cell culture stimulated for 4 hr with LPS 6.25 ng/ml with
and without treatment with 12 mM sodium acetate. Panel A shows representative
images of the Western blots. Panels B, D and F show the optical densities of the antiinflammatory cytokines TGF-β1, IL-4, and IL-10, respectively, normalized to the
loading control α-tubulin (n = 6). Panels C, E and G show the changes in the mRNA
levels of the anti-inflammatory cytokines TGF-β1, IL-4, and IL-10, quantified by qrtPCR and normalized to β-actin (n = 6). Bars represent means + SD where statistical
significance (a = compared to NaCl, and b = compared to LPS) was set at p ≤ 0.05, as
determined by a one way ANOVA followed by Tukey’s post-hoc test.
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Figure 18. Acetate treatment and the expression of anti-inflammatory cytokines in LPSstimulated BV-2 microglia.
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Acetate Treatment and LPS Alter MAPK Phosphorylation in a Time-dependent
Manner in BV-2 Microglia
Because MAPK signaling can be inhibited by the acetylation of MAPK
phosphatase-1 which induces deacetylation and deactivation of MAPK (Cao et al.
2008), we measured the effects of acetate treatment on LPS-induced MAPK
phosphorylation at 0.5, 1, 2, and 4 hr. The rationale for including multiple time points
is that other studies reported MAPK activation by LPS at much earlier time points than
4 hr (Schumann et al. 1996, Kraatz et al. 1998). Whole cell lysates were used for
Western blot analysis, and phosphorylated p38, p38, phosphorylated JNK, JNK,
phosphorylated ERK1/2 and ERK1/2 were detected as protein bands corresponding to
the molecular weights of 38, 38, 46, 54 and 46, and 42 and 46 kDa, respectively (Figure
19A). At 0.5 and 1 hr, neither LPS nor acetate treatment had an effect on the levels of
phosphorylated MAPK (Figures 19B-D). At 2 hr, acetate treatment reduced the level
of phosphorylated p38 as compared to LPS, and LPS increased JNK phosphorylation
by 5-fold, which was attenuated 2.5-fold with acetate treatment (Figures 19B and C).
At 4 hr, LPS increased phosphorylated p38 and phosphorylated JNK by 2-fold and was
not altered upon acetate treatment; however treatment did increase the level of
phosphorylated ERK1/2 by 2-fold only in the presence of LPS (Figures 19B-D).
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Figure 19. Acetate treatment and MAPK phosphorylation in LPS-stimulated BV-2
microglia.
Changes in the phosphorylation state of MAPK p38, JNK and ERK1/2 in BV-2
microglia stimulated for 0.5, 1, 2 and 4 hr with LPS 6.25 ng/ml with and without 12
mM sodium acetate. Panel A shows representative images of the Western blots from
the 4 hr experiment. Panels B, C and D show the optical densities of phosphorylated
MAPK p38, JNK and ERK1/2 normalized to the loading controls MAPK p38, JNK and
ERK1/2, respectively (n = 6). The data represent the means ± SD where statistical
significance (a = compared to NaCl, b = compared to LPS) was set at p < 0.05, as
determined by One Way ANOVA followed by Tukey’s post-hoc test.
Acetate Treatment Alters LPS-induced Increases in NF-κB p65 Protein Levels and
Phosphorylation at Serine 468 in BV-2 Microglia
Because NF-κB signaling is altered by acetylation of p65 (Kiernan et al. 2003,
Chen et al. 2001, Huang et al. 2010a) and has a prominent role in the regulation of
inflammatory and immune responses, we tested the effect of acetate treatment on LPSinduced changes in p65 protein levels, phosphorylation and acetylation after 4 hr of
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treatment. Whole cell lysates were used for Western blot analysis, and total p65,
phosphorylated p65 at serine 536, phosphorylated p65 at serine 468, and acetylated p65
at lysine 310 were detected as protein bands corresponding to the molecular weight of
65 kDa (Figure 20A). LPS increased the total protein level of p65 by 1.5-fold which
returned to control levels with acetate treatment (Figure 20B). While neither acetate
treatment nor LPS altered the level of phosphorylated p65 at serine 536, LPS did
increase the levels of phosphorylated p65 at serine 468 by 2-fold which was reduced to
control levels with acetate treatment (Figures 20C and D). In addition, acetate
treatment induced p65 hyperacetylation at lysine 310 by 3.5 and 4-fold depending on
the group (Figure 20E). These data suggest that acetate metabolism alters the LPSinduced p65 response in microglia, and that the anti-inflammatory effect of acetate
treatment can potentially be attributed to acetylation of non-histone targets.
In Figure 20, changes in the protein level, phosphorylation and acetylation
states of NF-κB p65 in BV-2 microglia cell culture stimulated for 4 hr with LPS 6.25
ng/ml with and without 12 mM sodium acetate. Panel A shows representative images
of the Western blots. Panel B shows the optical density of total NF-κB p65 normalized
to the loading control α-tubulin. Panels C, D and E show the optical densities of
phosphorylated p65 at S536, phosphorylated p65 at serine 468 and acetylFated p65 at
lysine 310 normalized to total p65, respectively (n = 6). The data represent the means ±
SD where statistical significance (a = compared to NaCl and b = compared to LPS) was
set at p < 0.05, as determined by One Way ANOVA followed by Tukey’s post-hoc test.
Abbreviations are: S536, serine 536; S468; serine 468: and K310, lysine 310.
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Figure 20. Acetate treatment and NF-κB p65 protein levels and modifications in LPSstimulated BV-2 microglia.
Optimizing the Duration of Acetate Treatment and LPS Concentration in Primary
Astroglial Cultures
To determine the duration of acetate treatment required to achieve H3K9
hyperacetylation pattern in vitro similar to that found in vivo (Soliman et al. 2012b), we
treated primary astrocytes with 12 mM sodium acetate for 1, 2 and 4 hr (Figures 21A
and B). Cell lysates were used for Western blot analysis to measure acetylated H3K9,
total histone H3 (Figure 21A). We found that acetate increased H3K9 acetylation at 1
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hr which remained increased out to 4 hr (Figure 21B). To insure protein expression
following treatment, we used 4 hr as the treatment duration for all the experiments. To
determine the optimal LPS concentration required to produce the same percentage of
H3K9 hypoacetylation in vitro similar to that found in vivo and in LPS-stimulated
microglia in vitro, using a serial dilution of LPS (0-25 ng/ml), we treated primary
astrocytes for 4 hr (Figures 21C and D-G). Cell lysates were used for Western blot
analysis to measure acetylated H3K9, total histone H3 and the pro-inflammatory
cytokines pro-IL-1β, IL-6, and TNF-α, which were detected as protein bands
corresponding to the molecular weights of 17, 17, 32, 25 and 17 kDa, respectively
(Figure 21C). Interestingly, LPS did not alter H3K9 acetylation or IL-6 protein levels
and increased pro-IL-1β and TNF-α protein levels in a concentration-dependent manner
(Figures 21D-G). Based on these data, we decided to use the LPS concentration 6.25
ng/ml because this concentration increased both pro-IL-1β and TNF-α protein levels,
and also to conform to the concentration used for the treatment of primary and BV-2
microglia.
In Figure 21, time-dependent acetate treatment-induced H3K9 hyperacetylation
and dose-response study showing the effects of different LPS concentrations (0-25
ng/ml, 4 hr) on H3K9 acetylation and the expression of pro-inflammatory cytokines in
primary mouse astrocyte cell culture. Panels A and C show representative images of
the Western blots. Panel B shows the averaged proportion of H3K9 normalized to total
H3 (n = 3) after 1, 2 and 4 hr of treatment with 12 mM sodium acetate. Panels D, E, F
and G show the optical densities of H3K9 normalized to total H3 and the pro-
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inflammatory cytokines pro-IL-1β, IL-6, and TNF-α normalized to the loading control
α-tubulin (n = 3). The graphs represent the means ± SD where statistical significance
(* = compared to control in panel B, and compared to LPS 0 ng/ml in panels D-G) was
set at p < 0.05, as determined by One Way ANOVA followed by Tukey’s post-hoc test.

Figure 21. Optimizing the duration of acetate treatment and LPS concentration in
primary astroglial cultures.
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Acetate Treatment causes H3K9 Hyperacetylation without Inducing Cytotoxicity
in LPS-stimulated Primary Astrocytes
In order to determine the effect of acetate on H3K9 acetylation in LPSchallenged astrocytes, we treated primary astrocyte cultures with 6.25 ng/ml LPS in the
presence and absence of 12 mM sodium acetate, and compared the results to cells
treated with 12 mM NaCl as a control group. Using whole cell lysates for Western blot
analysis, we found that primary astrocytes express acetyl-CoA synthetase; the enzyme
which converts acetate to acetyl-CoA, as protein bands corresponding to the molecular
weight of 79 kDa (Figure 22A). The expression levels of ACS were not different
between groups (Figure 22B). In addition, while LPS did not alter H3K9 acetylation,
acetate supplementation increased H3K9 acetylation by 2-fold in the presence and
absence of LPS challenge (Figure 22D). This finding is different than microglia where
the same concentration of LPS reduces H3K9 acetylation by about 50%. Measuring
cellular release of LDH as an index of cell death showed no difference in cell survival
between groups (Figure 22C). These data indicate that acetate treatment in vitro
induces H3K9 hyperacetylation in astrocytes similar to that found in vivo using oral
glyceryl triacetate in a rat model of neuroinflammation (Soliman et al. 2012b) and in
LPS-stimulated microglia in vitro (Soliman et al. 2012a), without altering acetyl-CoA
synthetase protein levels or inducing cell death.
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Figure 22. Acetate treatment and H3K9 acetylation in LPS-stimulated primary
astrocytes.
Changes in histone acetylation in primary mouse astrocyte cell culture
stimulated for 4 hr with LPS 6.25 ng/ml and/or 12 mM sodium acetate, with 12 mM
NaCl as control. Panel A shows representative images of the Western blots. Panels B
and D show the optical densities of acetyl-CoA synthetase enzyme normalized to the
loading control α-tubulin, and H3K9 normalized to total H3, respectively. Panel C
shows the quantification of the ratio of secreted LDH in the media to total cellular
LDH. Bars represent means + SD where statistical significance (* = compared to
NaCl, n = 4, 5, 4, and 5) was set at p ≤ 0.05, as determined by One Way ANOVA
followed by Tukey’s post-hoc test.
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Acetate Reverses LPS-induced Increases in the Pro-inflammatory Cytokine
Proteins, but not mRNA, in Primary Astrocytes
To determine the ability of acetate to reverse pro-inflammatory cytokine
production in vitro similar to that found in whole brain in vivo (Soliman et al. 2012b)
and in LPS-stimulated microglia in vitro (Soliman et al. 2012a), cell lysates were
analyzed using Western blot to probe for IL-1β, IL-6 and TNF-α (Figure 23A). We
found that LPS increased pro-IL-1β, TNF-α production, but not IL-6, by about 3.5 and
2.5-fold, respectively (Figure 23 B and F). Acetate treatment only partially attenuated
LPS-induced increases in pro-IL-1β (Figure 23B), completely reversed TNF-α (Figure
23F), and decreased IL-6 basal levels by about 40% (Figure 23D). Quantifying mRNA
using qrt-PCR showed that LPS increased the mRNA levels of the 3 pro-inflammatory
cytokines measured that were not altered by acetate treatment (Figures 23C and E) with
the exception of TNF-α mRNA which was only partially attenuated (Figure 23G).
Acetate Modulates the Expression of the Anti-inflammatory Cytokines in LPSchallenged Primary Astrocytes
Anti-inflammatory cytokines are produced during the inflammatory response as
a part of self-checking mechanisms, to mitigate the destructive effects of unopposed
pro-inflammatory mediators. We determined the effect of acetate treatment on
expression levels of the anti-inflammatory cytokine proteins TGF-β1, IL-4, and IL-10
in LPS-stimulated primary astrocytes (Figure 24A), that were detected as protein bands
corresponding to the molecular weights of around 25, 30 and 18 kDa, respectively.
Acetate treatment reversed the LPS-induced reduction in the TGF-β1 mRNA and
protein, and IL-4 protein (Figure 24B, C and D) and upregulated IL-4 mRNA by 3-fold
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and protein by 1.3-fold (Figure 24D and E). Interestingly, IL-10 mRNA was increased
by about 4-fold with acetate treatment, while the protein levels were decreased by 2fold. IL-10 protein and mRNA were not altered by LPS (Figure 24F and G). We
speculate that this could be due to either interference with mRNA translation, increased
protein turnover, or enhanced secretion into the extracellular milieu. Regardless, these
data suggest that acetate modulates pro- and anti-inflammatory cytokine in primary
astrocytes towards a more anti-inflammatory state similar to that found in LPSstimulated microglia (Soliman et al. 2012a).

Figure 23. Acetate treatment and the expression of pro-inflammatory cytokines in LPSstimulated primary astrocytes.
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Changes in the pro-inflammatory cytokines pro-IL-1β, IL-6, and TNF-α in
primary mouse astrocyte cell culture stimulated for 4 hr with LPS 6.25 ng/ml and/or 12
mM sodium acetate, with 12 mM NaCl as control. Panel A shows representative
images of the Western blots. Panels B, D and F show the optical densities of the proinflammatory cytokines pro-IL-1β, IL-6 and TNF-α, respectively, normalized to the
loading control α-tubulin (n = 6). Panels C, E and G show the changes in the mRNA
levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, quantified by qrt-PCR
and normalized to β-actin (n = 6). Bars represent means + SD where statistical
significance (a = compared to NaCl, and b = compared to LPS) was set at p ≤ 0.05, as
determined by One Way ANOVA followed by Tukey’s post-hoc test.
Acetate Reverses LPS-induced p38 Phosphorylation and Decreases Basal Levels of
ERK1/2 Phosphorylation in Primary Astrocyte Culture
MAPK inflammatory cascade is evidently involved in neuroinflammation and
pro-inflammatory cytokine production. Specific lysine acetylation was shown to
activate a MAPK phosphatase-1, which in turn deactivates MAPK signaling. This
sparked our interest to study the effects of acetate on LPS-induced MAPK
phosphorylation, and determine whether this is a potential mechanism of the antiinflammatory effect of acetate in primary astrocytes. Whole cell lysates were used for
Western blot analysis, and p38, phosphorylated p38, JNK, phosphorylated JNK,
ERK1/2, and phosphorylated ERK1/2 were detected as protein bands corresponding
with the molecular weights of around 38, 38, 46 and 54, 46 and kDa, 42 and 46, and 42
and 46 kDa, respectively (Figure 25A).
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Figure 24. Acetate treatment and the expression of the anti-inflammatory cytokines in
LPS- stimulated primary astrocytes.
Changes in the anti-inflammatory cytokines TGF-β1, IL-4, and IL-10 in
primary mouse astrocyte cell culture stimulated for 4 hr with LPS 6.25 ng/ml and/or 12
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mM sodium acetate, with 12 mM NaCl as control. Panel A shows representative
images of the Western blots. Panels B, D and F show the optical densities of the antiinflammatory cytokines TGF-β1, IL-4, and IL-10, respectively, normalized to the
loading control α-tubulin (n = 6). Panels C, E and G show the changes in the mRNA
levels of the anti-inflammatory cytokines TGF-β1, IL-4, and IL-10, quantified by qrtPCR and normalized to β-actin (n = 6). Bars represent means + SD where statistical
significance (a = compared to NaCl, and b = compared to LPS) was set at p ≤ 0.05, as
determined by One Way ANOVA followed by Tukey’s post-hoc test.
LPS increased p38 phosphorylation by 1.5-fold which was returned to control
level with acetate (Figure 25B). Neither LPS not acetate had an effect on JNK
phosphorylation (Figure 25C). While LPS did not alter ERK1/2 phosphorylation, the
basal levels of phosphorylated ERK1/2 were decreased by acetate treatment in the
presence and absence of LPS by almost 2-fold (Figure 25D). These data demonstrate
that acetate and LPS selectively modulate MAPK phosphorylation in primary
astrocytes in vitro, which can potentially represent a mechanism for the antiinflammatory effect of acetate treatment in astrocytes. This is different from microglia
where at 4 hr following LPS stimulation, MAPK p38 and JNK phosphorylation is
increased and is not altered by acetate treatment, and phosphorylated ERK1/2 that is
increased by acetate treatment only in the presence of LPS (Soliman et al. 2012a).
Acetate reverses LPS-induced elevated NF-κB p65 protein level, and decreases
the basal levels of p65 phosphorylation at serine 536 in primary astrocyte culture.
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Figure 25. Acetate treatment and MAPK phosphorylation in LPS-stimulated primary
astrocytes.
Changes in the phosphorylation state of MAPK p38, JNK and ERK1/2 in
primary mouse astrocyte cell culture stimulated for 4 hr with LPS 6.25 ng/ml and/or 12
mM sodium acetate, with 12 mM NaCl as control. Panel A shows representative
images of the Western blots. Panels B, C and D show the optical densities of
phosphorylated MAPK p38, JNK and ERK1/2 normalized to the loading controls
MAPK p38, JNK and ERK1/2, respectively (n = 6). The data represent the means ±
SD where statistical significance (a = compared to NaCl and b = compared to LPS) was
set at p < 0.05, as determined by One Way ANOVA followed by Tukey’s post-hoc test.
NF-κB is a major player in neuroinflammation and the biosynthesis of proinflammatory mediators. NF-κB p65 subunit is also regulated by a wide range of posttranslational modifications which have diverse functional consequences (Huang et al.
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2010a). In the light of this, we quantified the effects of LPS and acetate treatment on
NF-κB p65 protein levels and selected post-translational modifications using total cell
lysates for Western blot analysis. Total NF-κB p65 protein, acetylated p65 at lysine
310, and phosphorylated p65 at serine residues 468 and 536 were detected as protein
bands corresponding to the molecular weight 65 kDa (Figure 26). We found that while
LPS increased the protein levels of NF-κB p65 by 1.5-fold, acetate treatment reduced it
back to control levels (Figure 26B). Moreover, acetate treatment reduced the basal
level of phosphorylated p65 at serine 536 (Figure 26D). Neither LPS nor acetate
treatment altered acetylated p65 at lysine 310 or phosphorylated p65 at serine 468
(Figure 26C and E). These data suggest that acetate treatment can alter NF-κB p65
protein and selected post-translational modifications, which may explain the antiinflammatory effect of acetate treatment in LPS-challenged primary astrocytes.
Acetate Treatment and the Protein Levels of Phospholipases in LPS-stimulated
BV-2 Microglia
To determine the effect of LPS and acetate treatment on the phosphorylation
level of cPLA2 and the protein levels of total cPLA2, sPLA2 IIA and selected PLC
isoforms in BV-2 microglia, cells were treated with 6.25 ng/ml LPS in the presence and
absence of 12 mM sodium acetate, and compared the results to cells treated with 12
mM NaCl as a control group. Using whole cell lysates for Western blot analysis,
cPLA2, phosphorylated cPLA2, sPLA2 IIA, PLCβ1, PLCγ1, and PLCδ1 were detected
as protein bands corresponding to the molecular weight of 85, 85, 18, 150, 155, and 85
kDa, respectively (Figure 27A). The protein levels of total cPLA2 were not different
between groups (Figure 27B), whereas phosphorylated cPLA2 was increased with LPS
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1.5-fold which was not altered by acetate treatment (Figure 27C). The protein levels of
sPLA2 IIA, PLCγ1 and PLCδ1 were not altered by either LPS or acetate treatment
(Figure 27D, F and G). By contrast, LPS decreased PLCβ1 by 2-fold which was
reversed to control levels with acetate treatment (Figure 27E). These data suggest that
acetate treatment can alter cPLA2 phosphorylation and the protein levels of enzymes
involved in eicosanoid signaling in BV-2 microglia.

Figure 26. Acetate treatment and NF-κB p65 protein levels and modifications in LPSstimulated primary astrocytes.
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Changes in the protein level and phosphorylation and acetylation states of NFκB p65 in primary mouse astrocyte cell culture stimulated for 4 hr with LPS 6.25 ng/ml
and/or 12 mM sodium acetate, with 12 mM NaCl as control. Panel A shows
representative images of the Western blots. Panel B shows the optical density of total
NF-κB p65 normalized to the loading control α-tubulin. Panels C, D and E show the
optical densities of acetylated p65 at lysine 310, phosphorylated p65 at S536, and
phosphorylated p65 at serine 468, respectively (n = 6). The data represent the means ±
SD where statistical significance (a = compared to NaCl and b = compared to LPS) was
set at p < 0.05, as determined by One Way ANOVA followed by Tukey’s post-hoc test.
Acetate Treatment and the Protein Levels of Phospholipases in LPS-stimulated
Primary Astrocytes
To determine the effect of LPS and acetate treatment on the phosphorylation of
cPLA2 and the protein levels of total cPLA2, sPLA2 IIA and selected PLC isoforms in
astrocytes, primary astrocyte cultures were treated with 6.25 ng/ml LPS in the presence
and absence of 12 mM sodium acetate, and compared the results to cells treated with 12
mM NaCl as a control group. Whole cell lysates were used for Western blot analysis
(Figure 28A). The protein levels of total cPLA2 were not different between groups
(Figure 28B), whereas LPS increased phosphorylated cPLA2 by 2-fold which was
reversed to control levels by acetate treatment (Figure 28C). Acetate treatment
decreased the protein levels of sPLA2 IIA and PLCβ1 by 20% only in the presence of
LPS (Figure 28D and E). PLCγ1 and PLCδ1 protein levels were not altered by either
LPS or acetate treatment (Figure 28F and G). These data suggest that acetate treatment
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can alter cPLA2 phosphorylation and the protein levels of enzymes involved in the
eicosanoid signaling in primary astrocytes in a pattern different from BV-2 microglia.

Figure 27. Acetate treatment and phospholipases phosphorylation and protein levels in
LPS-stimulated BV-2 microglia.
Figure 27 shows the changes in the levels of cPLA2 phosphorylation and total
cPLA2, sPLA2 IIA, PLCβ1, PLCγ1 and PLCδ1 protein levels in BV-2 microglia
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cultures stimulated for 4 hr with LPS 6.25 ng/ml and/or 12 mM sodium acetate, with 12
mM NaCl as control. Panel A shows representative images of the Western blots.
Panels B, D, E, F and G show the optical densities total cPLA2, sPLA2 IIA, PLCβ1,
PLCγ1 and PLCδ1 normalized to the loading control α-tubulin. Panel C shows the
optical density of phosphorylated cPLA2 normalized to total cPLA2. Bars represent
means + SD where statistical significance (a = compared to NaCl, b = compared to
LPS, n = 6 per group) was set at p ≤ 0.05, as determined by One Way ANOVA
followed by Tukey’s post-hoc test.
Acetate Treatment and Cox-1 and 2 Levels in LPS-stimulated BV-2 Microglia and
Primary Astrocytes Culture
To determine the effect of acetate treatment downstream of cPLA2, the protein
levels of Cox-1 and 2 were measured in both LPS-stimulated BV-2 microglia and
primary astrocyte cell cultures. Using whole cell lysates for Western blot analysis,
Cox-1 and 2 were detected as protein bands corresponding to the molecular weights of
70 and 72 kDa, respectively (Figure 29A). In BV-2 microglia cultures, LPS increased
Cox-1 level by 1.5-fold which was completely reversed to control levels with acetate
(Figure 29B), and Cox-2 by 4-fold which was only partially attenuated by acetate
treatment (Figure 29C). In astrocyte cultures, LPS increased the protein levels of Cox1 by 1.5-fold which was reversed to control levels with acetate treatment (Figure 29D)
and Cox-2 by about 2.9-fold which was not altered by acetate treatment (Figure 29E).
However, the basal levels of Cox-2 were reduced by 2-fold by acetate treatment only in
the absence of LPS (Figure 29E). These data suggest that acetate treatment
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differentially modulates the levels of Cox-1 and 2 in LPS-challenged BV-2 microglia
and primary astrocytes cultures.

Figure 28. Acetate treatment and phospholipases phosphorylation and protein levels in
LPS-stimulated primary astrocytes.
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Figure 28 shows the changes in the levels of cPLA2 phosphorylation and total
cPLA2, sPLA2 IIA, PLCβ1, PLCγ1 and PLCδ1 protein levels in primary astrocyte cell
cultures stimulated for 4 hr with LPS 6.25 ng/ml and/or 12 mM sodium acetate, with 12
mM NaCl as control. Panel A shows representative images of the Western blots.
Panels B, D, E, F and G show the optical densities total cPLA2, sPLA2 IIA, PLCβ1,
PLCγ1 and PLCδ1 normalized to the loading control α-tubulin. Panel C shows the
optical density of phosphorylated cPLA2 normalized to total cPLA2. Bars represent
means + SD where statistical significance (a = compared to NaCl, b = compared to
LPS, n = 6 per group) was set at p ≤ 0.05, as determined by One Way ANOVA
followed by Tukey’s post-hoc test.

Figure 29. Acetate treatment and the protein levels of cyclooxygenases in LPSstimulated BV-2 microglia and primary astrocytes.
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Figure 29 shows the changes in the total Cox-1 and Cox-2 protein levels in BV2 microglia and primary astrocyte cell cultures stimulated for 4 hr with LPS 6.25 ng/ml
and/or 12 mM sodium acetate, with 12 mM NaCl as control. Panel A shows
representative images of the Western blots. Panels B and C show the optical densities
of Cox-1 and Cox 2, respectively normalized to the loading control α-tubulin in BV-2
microglial cell cultures. Panels D and E show the optical densities of Cox-1 and Cox 2,
respectively normalized to the loading control α-tubulin in primary astrocyte cell
cultures. Bars represent means + SD where statistical significance (a = compared to
NaCl, b = compared to LPS, n = 6 per group) was set at p ≤ 0.05, as determined by One
Way ANOVA followed by Tukey’s post-hoc test.
Acetate Treatment and the Production of Prostaglandin E2 in LPS-stimulated BV2 Microglia and Primary Astrocyte Cultures
Having demonstrated the ability of acetate treatment to alter cPLA2
phosphorylation and sPLA2 IIA, Cox-1 and 2 protein levels, we proceeded to determine
whether acetate treatment had functional effects in terms of PG release. The media
from LPS-stimulated BV2-microglia and primary astrocyte cultures were used to
quantify PGE2 using enzyme immunoassay kit. PGE2 levels were not altered by either
LPS or acetate treatment in BV-2 microglia cultures (Figure 30A), whereas LPS
increased PGE2 levels by 4-fold in astrocyte cultures which was completely reversed to
control levels with acetate treatment (Figure 30B). These data suggest that acetate
treatment can differentially modulate PGE2 release, which may contribute to the antiinflammatory effect of acetate in LPS-stimulated astrocytes.
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Figure 30. Acetate treatment and the release of prostaglandin E2 in LPS-stimulated BV2 microglia and primary astrocytes.
Figure 30 shows the changes in the levels of PGE2 secreted in the media of BV2 microglia (panel A) and primary astrocyte cell cultures (panel B) stimulated for 4 hr
with LPS 6.25 ng/ml and/or 12 mM sodium acetate, with 12 mM NaCl as control.
PGE2 levels were measured using enzyme immunoassay. Bars represent means + SD
where statistical significance (a = compared to NaCl, b = compared to LPS, n = 6 per
group) was set at p ≤ 0.05, as determined by One Way ANOVA followed by Tukey’s
post-hoc test.
Acetate Treatment and the Enrichment of Acetylated H3K9 around the
Transcription Start Sites of Inflammatory Genes in LPS-stimulated BV-2
Microglia Cell Cultures
Acetate treatment increases H3K9 acetylation in vivo (Soliman & Rosenberger
2011, Soliman et al. 2012b) and in vitro (Soliman et al. 2012a), reverses LPS-induced
increase in NF-κB p65 protein but not IL-1β mRNA, and increases IL-4 mRNA
(Soliman et al. 2012a). Because histone acetylation changes are associated with
alterations in gene expression (Rice & Allis 2001, Strahl & Allis 2000), the enrichment
of acetylated H3K9 around the promoters of ptgs1, ptgs2 (coding for Cox-1 and Cox-2,
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respectively), p65, il4 and il1b genes was measured using chromatin
immunoprecipitation. Five different primer sets were prepared for each of these genes,
except il1b (4 primer sets) spanning different genomic stretches between -750 base
pairs and +1000 base pairs (Table 1). Acetate treatment increased acetylated H3K9 as
detected using primer sets # 2, 3 and 5 for ptgs1 (Figure 31A) and primer set # 5 for
ptgs2 (Figure 31B). In addition, acetate treatment was found to increase acetylated
H3K9 as detected using primer sets # 1, 2 and 4 for p65 (Figure 31C), and primer sets #
2, 3 and 4 for il1b (Figure 31E) and did not alter acetylation H3K9 at il4 (Figure 31D).
LPS did not alter the levels of acetylated H3K9, except for a small reduction observed
using primer set # 2 for ptgs1 which was reversed to control levels with acetate
treatment (Figure 31A). These data suggest that acetate treatment alters acetylated
H3K9 at the promoters of genes involved in inflammatory signaling, which may
potentially influence inflammatory gene expression.
During the preparation of these primer sets, we used the mouse genome browser
of the University of California, Santa Cruz at http://genome.ucsc.edu/cgibin/hgGateway; the December 2011 assembly. To calculate the properties of the
primers (length, melting temperature, and GC content), we used the online
oligonucleotide properties calculator available at http://www.basic.northwestern.edu/
biotools/oligocalc.html. The (-) and (+) signs mean upstream and downstream,
respectively in reference to the transcription start site. For each gene, we designed 2
primer sets spanning genomic sequences upstream to the transcription start site (up to
750 base pairs), 2 primer sets spanning genomic sequences downstream to the
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transcription start site (up to 1000 base pairs) and one primer set spanning the
transcription start site.

Figure 31: Acetate treatment and the enrichment of acetylated H3K9 around the
transcription start sites of inflammatory genes in LPS-stimulated BV-2 microglia
cultures.
Figure 31 shows the changes in the levels of enrichment of acetylated H3K9 at
ptgs1 (panel A), ptgs2 (panel B), p65 (panel C), il4 (panel D), and il1b (panel E) genes
measured by chromatin immunoprecipitation analysis followed by qrt-PCR, in BV-2
microglial cell cultures stimulated for 4 hr with LPS 6.25 ng/ml and/or 12 mM sodium
acetate, with 12 mM NaCl as control. Bars represent means + SD where statistical
significance (a = compared to NaCl, b = compared to LPS, n = 3 per group) was set at p
≤ 0.05, as determined by One Way ANOVA followed by Tukey’s post-hoc test.
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ptgs1

Gene

Primer Set #3

Primer Set #2

Primer Set #1

Primer Set

Reverse

Forward

Reverse

Forward

Reverse

Forward

CAA CTC
CCC TCA
CCT TTA
ACT AT
CTT GCT
GGT CCT
CGG TGT AT
TCA TGT
CTG ACC
TGG CCT CT
TGG GAT
ATA GCA
AAC TGA
GGC
GCA TTT
CTG ACA
CTG TAA
AAA GAT C
GGG AGT
GGA TGG
ATG TGC
AA

Sequence

+112

-129

-157

-393

-468

-736

Start

+131

-105

-137

-374

-449

-714

End

20

25

21

20

20

23

Length

60.5

60.9

59.5

60.5

60.5

60.9

Melting Temperature (° C)

Table Listing the Nucleotide Sequence of the Primers used in the Chromatin Immunoprecipitation Analysis

Table 1

261

257

288

Amplicon Size
(bp)

94

96

ptgs2

Primer Set #4

ptgs1

Primer Set #2

Primer Set #1

Primer Set #5

Primer Set

Gene

Table 1 (continued)

Reverse

Forward

Reverse

Forward

Reverse

Forward

Reverse

Forward

ACA CCC
TCG GTC
CTG CTC1
AGA ACC
TGT CTC
TGC TTC CC
TTG GGG
AGG AAG
CGG CAG
ACT TGG
GGC TGT
TAT CGC AC
CTA TGT
AAC AGC
AGG GGG
AAA AT
GCA CAC
AGC TAC
CGG TTA
ATT T
TGA GCT
TTT AGG
CCC CCA CT
AGG CTT
TTA CCC
ACG CAA
ATG A

Sequence

-196

-373

-499

-720

+869

+668

+550

+296

Start

-175

-354

-478

-698

+888

+685

+569

+313

End

22

20

22

23

20

18

20

18

Length

60.1

60.5

60.1

60.9

60.1

60.8

60.5

60.8

Melting Temperature (° C)

199

243

221

274

Amplicon Size
(bp)

95

P65

Primer Set #3

Ptgs2

Primer Set #1

Primer Set #5

Primer Set #4

Primer Set

Gene

Table 1 (continued)

Reverse

Forward

Reverse

Forward

Reverse

Forward

Reverse

Forward

AAA GTT
GGT GGG
GGT TGG G
GCA GCG
CAG AGC
AGC AC
CTG CAA
CCC ACT
TTC AGG
TTT
CGA CCT
AGT GCA
ATA GTC
AAA ATT
TTA TCA
TTG TAA
AGT TGA
CCC ATA GT
AGG AAG
ATA CCC
CAG GAA
AAA CT
CAA CTC
CCC TCA
CCT TTA
ACT AT
CTT GCT
GGT CCT
CGG TGT AT

Sequence

-557

-743

+971

+750

+511

+265

+116

-131

Start

-535

-720

+993

+775

+534

+285

+132

-113

End

23

24

23

26

24

21

17

19

Length

60.9

60.3

60.9

60.1

60.3

59.5

59.8

59.5

Melting Temperature (° C)

209

244

270

264

Amplicon Size
(bp)
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Primer Set #2

P65

Primer Set #5

Primer Set #4

Primer Set #3

Primer Set

Gene

Table 1 (continued)

Reverse

Forward

Reverse

Forward

Reverse

Forward

Reverse

Forward

TCA TGT
CTG ACC
TGG CCT CT
TGG GAT
ATA GCA
AAC TGA
GGC
GCA TTT
CTG ACA
CTG TAA
AAA GAT C
GGG AGT
GGA TGG
ATG TGC
AA
ACA CCC
TCG GTC
CTG CTC
AGA ACC
TGT CTC
TGC TTC CC
TTG GGG
AGG AAG
CGG CAG
ACT TGG
GGC TGT
TAT CGC AC

Sequence

+773

+538

+272

+146

+75

-93

-336

-518

Start

+792

+555

+293

+163

+92

-71

-318

-499

End

20

18

22

18

18

23

19

20

Length

60.5

60.8

60.1

60.8

60.8

60.9

61.6

60.5

Melting Temperature (° C)

255

148

186

201

Amplicon Size
(bp)
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il1β

Gene

Primer Set #4

Primer Set #3

Primer Set#2

Primer Set #1

Primer Set

Table 1 (continued)

Reverse

Forward

Reverse

Forward

Reverse

Forward

Reverse

Forward

CAA CTC
CCC TCA
CCT TTA
ACT AT
CTT GCT
GGT CCT
CGG TGT AT
TCA TGT
CTG ACC
TGG CCT CT
TGG GAT
ATA GCA
AAC TGA
GGC
GCA TTT
CTG ACA
CTG TAA
AAA GAT C
GGG AGT
GGA TGG
ATG TGC
AA
TTG GGG
AGG AAG
CGG CAG
ACT TGG
GGC TGT
TAT CGC AC

Sequence

+794

+550

+89

-125

-229

-450

-516

-749

Start

+815

+575

+111

-103

-210

-429

-496

-730

End

22

26

23

23

20

22

20

20

Length

60.1

60.1

60.9

60.9

60.5

60.1

60.5

60.5

Melting Temperature (° C)

266

237

241

253

Amplicon Size
(bp)
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il4

Gene

Primer Set #4

Primer Set #3

Primer Set #2

Primer Set #1

Primer Set

Table 1 (continued)

Reverse

Forward

Reverse

Forward

Reverse

Forward

Reverse

Forward

CAA CTC
CCC TCA
CCT TTA
ACT AT
CTT GCT
GGT CCT
CGG TGT AT
TCA TGT
CTG ACC
TGG CCT CT
TGG GAT
ATA GCA
AAC TGA
GGC
GCA TTT
CTG ACA
CTG TAA
AAA GAT C
GGG AGT
GGA TGG
ATG TGC
AA
ACA CCC
TCG GTC
CTG CTC
AGA ACC
TGT CTC
TGC TTC CC

Sequence

+404

+151

+82

-113

-239

-449

-517

-748

Start

+428

+173

+104

-91

-214

-427

-498

-729

End

25

23

23

23

26

23

20

20

Length

60.9

60.9

60.9

60.9

60.1

60.9

60.5

60.5

Melting Temperature (° C)

278

218

236

251

Amplicon Size
(bp)
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il4

Gene

Primer Set #5

Primer Set

Table 1 (continued)

Reverse

Forward

TTG GGG
AGG AAG
CGG CAG
ACT TGG
GGC TGT
TAT CGC AC

Sequence

+713

+602

Start

+735

+624

End

23

23

Length

60.9

60.9

Melting Temperature (° C)

134

Amplicon Size
(bp)

Acetate Treatment Modulates the Expression of a Selected Subset of
Inflammatory Genes
We addressed the question of whether acetate treatment alters global gene
expression or the expression of selective inflammatory genes. Using qrt-PCR array, we
quantified the effect of long-term acetate treatment on the expression of 84 genes that
are involved in the innate and adaptive immune responses in rat brain. Only six genes
out of a total of 84 showed more than 0.5-fold change from the control values. These 6
genes were aodra2a, il1b, il1rn, mapk14, nfkb1 and tnf which code for adenosine A2a
receptor, IL-1β, IL-1 receptor antagonist, MAPK p38, NF-κB 105 kDa protein subunit
and TNF (Table 2). The change in only adenosine A2a receptor expression was
statistically significant. These results support the findings that acetate treatment can
alter the expression of genes involved in the inflammatory and immune responses and
suggest that acetate treatment modulates gene expression in a selected subset of genes
and does not induce global gene expression changes.
Table 2 shows the gene symbols, description and fold changes elicited by longterm acetate supplementation in the expression of 84 genes involved in the innate and
adaptive immune responses in rat brain, (n = 2). The last five genes coding for a large
ribosomal subunit protein P1, hypoxanthine phosphoribosyltransferase 1, ribosomal
protein L13A, lactate dehydrogenase A, β-actin are controls. Data analysis was
performed using SABiosciences online data analysis tool.
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Table 2
Acetate Treatment and Expression of Genes involved Innate and Adaptive Immune
Responses
#

Symbol

Description

Fold
Change

1

Adora2a

Adenosine A2a receptor

8.66

2

C5

Complement component 5

1.14

3

C8a

Complement component 8, alpha
polypeptide

1.14

4

Camp

Cathelicidin antimicrobial peptide

0.93

5

Casp1

Caspase 1

1.44

6

Casp4

Caspase 4, apoptosis-related cysteine
peptidase

1.34

7

Cc12

Chemokine (C-C motif) ligand 2

1.90

8

Ccr3

Chemokine (C-C motif) receptor 3

1.14

9

Cd14

CD14 molecule

1.14

10

Cd1d1

CD1d1 molecule

1.14

11

Cd55

Cd55 molecule

1.34

12

Cfp

Complement factor properdin

1.26

13

Chuk

Conserved helix-loop-helix ubiquitous
kinase

0.69

14

Clec7a

C-type lectin domain family 7, member a

1.14

15

Colec12

Collection sub-family member 12

0.57

16

Crjp

C-reactive protein, pentraxin-related

1.14
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Table 2 (continued)
#

Symbol

Description

17

Cxcr4

Chemokine (C-X-C motif) receptor 4

Fold
Change
1.14

18

Cybb

Cytochrome b-245, beta plypeptide

1.05

19

Defb4

Defensin beta 4

1.14

20

Dmbt1

Deleted in malignant brain tumors 1

1.14

21

Fn1

Fibronectin 1

0.61

22

Hmox1

Heme oxygenase (decycling) 1

1.23

23

Ifna1

Interferon-alpha 1

1.14

24

Ifnb1

Interferon beta 1, fibroblast

1.14

25

Ifngr1

Interferon gamma receptor 1

1.10

26

Ifngr2

Interferon gamma receptor 2

0.69

27

Ikbkb

Inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase beta

0.83

28

I110

Interleukin 10

1.14

29

I112rb2

Interleukin 12 receptor, beta 2

0.68

30

I11a

Interleukin 1 alpha

1.04

31

I11b

Interleukin 1 beta

1.54

32

I11f10

Interleukin 1 family, member 10

1.14

33

I11f5

Interleukin 1 family, member 5 (delta)

1.14

34

I11f6

Interleukin 1 family, member 6

1.14
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Table 2 (continued)
#

Symbol

Description

Fold
Change

35

I11f8

Interleukin 1 family, member 8

1.14

36

I11fp

Interleukin 1 family, member 9

1.14

37

I11r1

Interleukin 1 receptor, type I

0.94

38

I11r2

Interleukin 1 receptor, type II

1.14

39

I11rap

Interleukin 1 receptor accessory protein

1.14

40

I11rap12

Interleukin 1 receptor accessory proteinlike 2

0.75

41

I11r12

Interleukin 1 receptor-like 2

1.14

42

I11m

Interleukin 1 receptor antagonist

0.48

43

I16

Interleukin 6

1.14

44

Irak1

Interleukin-1 receptor-associated kinase 1

0.64

45

Irak2

Interleukin-1 receptor-associated kinase 2

1.14

46

Irf1

Interferon regulatory factor 1

0.91

47

Lalba

Lactalbumin, alpha

1.14

48

Lbp

Lipopolysaccharide binding protein

1.14

49

Lck

Lymphocyte-specific protein tyrosine
kinase

1.14

50

Ly96

Lymphocyte antigen 96

0.97

51

Lyz2

Lysozyme 2

0.65

52

Mapk14

Mitogen activated protein kinase 14

2.36
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Table 2 (continued)
#

Symbol

Description

Fold
Change

53

Mapk8

Mitogen-activated protein kinase 8

0.60

54

Mif

Macrophage migration inhibitory factor

1.17

55

Myd88

Myeloid differentiation primary response
gene 88

0.74

56

Ncf4

Neutrophil cytosolic factor 4

1.14

57

Nfkb1

Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1

2.97

58

Nfkb2

Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2, p49/p100

1.15

59

Nfkbia

Nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha

0.93

60

Nirc4

NLR family, CARD domain containing 4

1.14

61

Nos2

Nitric oxide synthase 2, inducible

1.14

62

Pglyrp1

Peptidoglycan recognition protein 1

1.05

63

Pglyrp3

Peptidoglycan recognition protein 3

1.14

64

Ppbp

Pro-platelet basic protein (chemokine (CX-C motif) ligand 7)

1.14

65

Prg2

Proteoglycan 2, bone marrow

0.85

66

Proc

Protein C

1.14

67

Ptafr

Platelet-activating factor receptor

1.10

68

Serpina 1

Serpin peptidase inhibitor, clade A (alpha1 antiproteinase, antitrypsin), member 1

1.15
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Table 2 (continued)
#

Symbol

Description

Fold
Change

69

Serpina 1

Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1

1.14

70

Sftpd

Surfactant protein D

1.14

71

Stabilin 1

1.14

72

LOC100363
145
Tgfb1

Transforming growth factor, beta 1

0.69

73

T1r1

Toll-like receptor 1

1.30

74

T1r10

Toll-like receptor 10

1.14

75

T1r2

Toll-like receptor 2

0.97

76

T1r3

Toll-like receptor 3

0.76

77

T1r4

Toll-like receptor 4

0.72

78

T1r6

Toll-like receptor 6

1.03

79

T1r9

Toll-like receptor 9

1.14

80

Tnf

Tumor necrosis factor (TNF superfamily,
member 2)

2.59

81

Tnfrsf1a

Tumor necrosis factor receptor
superfamily, member 1 a

1.14

82

Tollip

Toll interacting protein

1.05

83

Traf6

Tnf receptor-associated factor 6

0.64

84

Trem1

Triggering receptor expressed on myeloid
cells 1

1.14

85

Rplp1

Ribosomal protein, large, P1

1.16
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Table 2 (continued)
#

Symbol

Description

86

Hprt1

Hypoxanthine phosphoribosyltransferase 1

Fold
Change
0.96

87

Rp113a

Ribosomal protein L13A

1.08

88

Ldha

Lactate dehydrogenase A

0.71

89

Actb

Actin, beta

0.97
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CHAPTER IV
DISCUSSION
Preferential Uptake and Utilization of Acetate
Acetate has long been used as a substrate to study glial metabolism (Thoren et
al. 2005, Wyss et al. 2011, Wyss et al. 2009), particularly because it is preferentially
utilized by astrocytes (Waniewski & Martin 1998, Hosoi et al. 2009, Muir et al. 1986).
Peripherally-derived acetate crosses the blood brain barrier by simple diffusion
(Oldendorf 1973, Terasaki 1992). The rate-limiting step of acetate utilization is its
activation by acetyl-CoA synthetase to form acetyl-CoA. The transport of acetate into
the cell is through a carrier that has similar biochemical properties to monocarboxylate
transporters (MCTs), a number of which were cloned, differ in organ distribution, and
have different substrate and inhibitor affinities (Garcia et al. 1994b, Garcia et al.
1994a). Earlier reports demonstrated MCT1 is expressed in astrocytes while MCT2 is
expressed in the neurons (Broer et al. 1997, Pierre et al. 2000), and later reports
demonstrated the cell type-specific expression of MCTs 1, 2 and 4 in the brain based on
age (Rafiki et al. 2003). The presence of different MCT isoforms in astrocytes than in
neurons explains the differential utilization of acetate by astrocytes, particularly
because acetyl-CoA synthetase is not expressed differently between cell types and even
has greater activity in neurons than in astrocytes. Altogether, the ability of astrocytes to
utilize acetate is well-established; however, the novelty of our studies stems from
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investigating the mechanisms by which acetate treatment can be anti-inflammatory in
glial cells. We tested the hypothesis that acetate alters histone acetylation and disrupts
inflammatory signaling in vivo and in vitro, as an attempt to explain the antiinflammatory effects of acetate we observed in a rat model of LPS-induced
neuroinflammation (Reisenauer et al. 2011).
Metabolic Channels for Acetyl-CoA Utilization
Acetate supplementation using glyceryl triacetate increases brain levels of acetate
17-fold 1 hr after treatment with a dose of 5.8 g/kg (Mathew et al. 2005). Glyceryl
triacetate-derived acetate is converted to metabolically active acetyl-CoA by 30 min
following treatment and brain levels remain significantly elevated for up to 4 hr
(Reisenauer et al. 2011). Acetyl-CoA has numerous roles in metabolism and biological
processes in brain. For example, in oligodendrocyte cytosol, acetyl-CoA is the source
of the units of two carbon atoms used for fatty acid elongation which parallels myelin
deposition (Bourre et al. 1977). In addition, it can be used as a substrate for ketone
bodies, fatty acids and cholesterol biosynthesis, and oxidation in Krebs cycle for energy
generation after condensing with oxaloacetate to form citrate (Fukao et al. 2004,
McGarry & Foster 1980, Deutsch et al. 2002, Des Rosiers et al. 1991).
Acetyltransferases use acetyl-CoA as acetyl donor for post-translational acetylation
reactions on lysine and arginine residues which can lead to structural and functional
consequences in proteins.
At the onset of these studies, we proposed that a possible therapeutic
mechanism of action by which acetate reduces neuroinflammatory phenotype is by
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altering brain histone acetylation. To test this hypothesis, we examined the ability of a
single oral dose of glyceryl triacetate (6 g/kg) to effectively alter brain histone
acetylation state. These results suggest that acetate supplementation significantly
increases the acetylation of brain histones H3K9, H4K8, and H4K16 while having no
effect on the acetylation state of brain histones H3K14, H4K5, or H4K12. Moreover,
acetate supplementation inhibited HDAC activity and decreased HDAC2 protein levels
in brain without altering HAT activity. In order to begin to determine the mechanism
by which acetate supplementation decreases HDAC activity, we examined the protein
levels of several HDAC. Of the known HDAC, class I and II HDAC are known to be
primarily involved in the regulation of histone acetylation. While we did not observe
significant changes in HDAC1, 3, 4, 5 or 7, we found HDAC2 levels were significantly
decreased at 4 hr post-treatment. The decrease in HDAC activity reported in this study
coincides with the time points measured when HDAC2 protein levels were decreased
and brain histone acetylation states were increased. The temporal relationship between
increased histone acetylation and HDAC inhibition suggests that HDAC inhibition is a
possible mechanism by which acetate supplementation can alter brain histone
acetylation state.
The temporal and histone specific changes found in this study suggest that
specific inhibition of HDAC2 may lead to preferential and possible therapeutically
beneficial increases in the acetylation of specific histone lysine residues. This premise
is supported by studies showing that HDAC maintain substrate specificity in terms of
the particular histone lysine residues they deacetylate. For example, Rpd3p
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preferentially deacetylates histones H4K5 and H4K12 and promotes hypoacetylation in
yeast (Peterson 2002) and the diacetylation of histone H4 follows a specific nonrandom pattern at H4K16 and H4K8 (Clarke et al. 1993, Thorne et al. 1990, Turner et
al. 1989). On the other hand, the acetylation of histone H4K5 and H4K12 is mainly
restricted to the newly synthesized histone H4, and that acetylation of H4K8 and
H4K16 inhibits the acetylation of H4K5 and H4K12 (Makowski et al. 2001). This data
provides support for the premise that site-specific acetylation of histones can regulate
the acetylation of other substrate sites and that elevated brain acetyl-CoA may result in
specific HDAC inhibition.
Mechanisms of Action of HDAC Inhibitors
The HDAC inhibitors SAHA, MS 275, valproic acid, and TSA work on the
catalytic site of the enzyme. These inhibitors function by; (a) chelating or displacing
the zinc ions, (b) forming a hydrophobic spacer spanning the entire length of the
HDAC enzyme hydrophobic active site, (c) acting as a hydrophobic cap preventing
substrate binding and, (d) inducing ubiquitination and subsequent proteasomal
degradation of the enzyme (Santini et al. 2007). Acetate supplementation has not been
described previously as an inhibitor of HDAC activity; however, we demonstrate that
acetylation caused by acetate supplementation may be a result of an inhibition of
HDAC activity and expression independent of HAT activation. HDAC inhibition by
acetate supplementation can, in addition, be explained by the fact that the increased
tissue levels of acetyl-CoA exert endpoint inhibition of HDAC activity, thus hindering
the removal of acetyl groups from the N-terminal tail of histone. Nevertheless, because
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the regulatory mechanisms controlling histone acetylation and HDAC enzyme activity
are numerous, the results demonstrated with a single oral dose of acetate cannot
exclude the possibility of acetate altering other mechanisms such as acetylation of nonhistone proteins, inducting other post-translational modifications of histones and
transcriptional factors, or altering the activity of other HDAC.
Histone Acetylation Correlates with Anti-inflammatory and Neuroprotective
Properties
Translational research and clinical trials are being executed to test the
effectiveness of HDAC inhibitors as alternatives to non-steroidal anti-inflammatory
drugs as well as being anti-neoplastic through inducing a hyperacetylation state. The
association of histone hyperacetylation with anti-inflammatory effects is clearly
demonstrated by a wide range of studies showing that a number of HDAC inhibitors
ameliorate symptoms of Huntington’s disease, spinal and bulbar muscular atrophy,
Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, spinal muscular
atrophy, and Friedreich’s ataxia (Adcock 2007, Blanchard & Chipoy 2005, Langley et
al. 2005, Morrison et al. 2007). The functional significance of site-specific histone
acetylation remains unclear; however, the acetylation of certain lysine residues has
been associated with beneficial biological outcomes. For example, an increase in
acetylated H3K9 following valproic acid treatment, a class I HDAC inhibitor, protects
neurons against hypoxia-induced neuronal apoptosis (Li et al. 2008). Similarly,
increased acetylated H3K9 is associated with attenuating microglial activation in an
animal model of traumatic brain injury (Zhang et al. 2008). The preferential
hyperacetylation of brain H4K16 is recognized as a central switch in higher-order
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chromatin structure (Shogren-Knaak et al. 2006). When arranged into nucleosomal
arrays, acetylated H4K16 inhibits the formation of higher-order 30 nm chromatin fibers
and therefore leads to activation of gene expression. Moreover, H4K16 acetylation is
thought to play a unique role in DNA repair due to its being defective in aging and
neurodegenerative disorders (Li et al. 2010). In this regard, both H4K16 and H4K8
acetylation were increased following a single oral dose of glyceryl triacetate as well as
with long-term acetate supplementation. All of which support the premise that specific
alterations in histone acetylation can be potentially therapeutic. These results suggest
that a potential mechanism by which acetate supplementation may be effective at
attenuating neuroinflammation is by altering higher-order chromatin structure and
reducing pro-inflammatory gene expression. In support of this notion, H4K12
acetylation, which was not altered in our model, is implicated in gene silencing
(Braunstein et al. 1996). The acetylation state at H4K16 is also an epigenetic hallmark
for certain cancers, including leukemia, lymphoma, and colorectal adenocarcinoma cell
lines, in which H4K16 hyperacetylation is lost (Fraga et al. 2005, Fraga & Esteller
2005).
Discrepancies between the Effects of a Single Dose of Acetate and Long-term
Acetate Supplementation
Long-term acetate supplementation decreases neuroglia activation and
cholinergic cell loss in a rat model of neuroinflammation (Reisenauer et al. 2011). A
single oral dose increases histone acetylation, decreases HDAC activity, and decreases
HDAC2 protein levels (Soliman & Rosenberger 2011). For these reasons and because
histone hyperacetylation is associated with anti-inflammatory phenotypes (Adcock
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2007) and can alter gene expression (Strahl & Allis 2000), we proposed that acetate
supplementation reverses LPS-induced histone acetylation changes, and is associated
with reduction of the pro-inflammatory gene expression. To begin to test this
hypothesis we quantified the ability of long-term acetate supplementation to increase
brain histone acetylation, to alter HAT and HDAC enzyme activities, and to decrease
the expression of the pro-inflammatory cytokine IL-1β in a rat model of LPS-induced
neuroinflammation. Unlike a single dose of glyceryl triacetate, long-term acetate
supplementation increased HAT activity and had no effect on total brain HDAC
activity, with variable effects on brain HDAC class I & II expression. In agreement
with our hypothesis, neuroinflammation reduced the proportion of brain H3K9
acetylation by 50% and increased IL-1β protein and mRNA levels by 1.3- and 10- fold,
respectively, all of which were effectively reversed with long-term acetate
supplementation.
Evaluating the effect of neuroinflammation on brain histone acetylation in
parallel with the drug effect found in the control and treated rats suggest that H3K9
acetylation and possibly HDAC7 activity may be directly involved in injury
progression in this model. For example, as outlined in figure 8B, LPS-induced
neuroinflammation resulted in a direct reduction in H3K9 acetylation that was reversed
with acetate supplementation. This finding is corroborated by other reports showing
that the use of a HDAC inhibitor DMA-PB decreases microglial activation in a rat
model of traumatic brain injury, and that this anti-inflammatory effect is associated
with increased histone H3 acetylation (Zhang et al. 2008). Further, the proportion of
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acetylated H3K9 is significantly lower in livers of aged rats, suggesting that the
acetylation of H3K9 may be required to maintain essential cellular functions
(Kawakami et al. 2009). Similarly, we found that the expression of HDAC7 was
increased in rats subjected to LPS-induced neuroinflammation that was again reversed
with long-term acetate supplementation. This suggests that mechanisms are in place
that may account for injury- and treatment-specific changes in histone acetylation. In
contrast, the acetylation state of H3K14 was not altered by acetate supplementation or
LPS-induced neuroinflammation suggesting that H3K14 acetylation was not related to
treatment or neuroinflammation.
Another discrepancy between the effects of a single oral dose of acetate versus
long-term acetate supplementation is that a single treatment decreases brain HDAC
activity, whereas long-term supplementation had no effect on total brain HDAC
activity, despite multiple alterations in the expression of individual HDAC. This can be
explained by the fact that HDAC assays performed in this study measured overall
HDAC activity and were reflective of the sum of all the individual HDAC. Given the
differences in HDAC expression (i.e. increased brain HDAC1, 2 & 7 and decreased
brain HDAC3), we believe that the histone acetylation pattern found in this study is a
reflection of the substrate specificity of the specific HDAC expressed following
treatment despite no overall change in total brain HDAC activity. We speculate that
the increased expression of HDAC1 and HDAC2 is a physiological response to longterm acetate supplementation and an increase in brain acetyl-CoA levels. Further,
HDAC activity does not depend solely on the expression of HDAC, but rather work in
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concert with co-regulatory repressive complexes to modify catalytic activity (de Ruijter
et al. 2003). For example, cloned HDAC and purified HDAC do not have
deacetylating activity in vitro due to the lack of other protein complexes found in vivo
(Saha & Pahan 2006). Therefore, HDAC activity is not expected to increase unless the
increase in HDAC expression is paralleled by an increase in the expression of coregulatory complexes. Moreover, we do not exclude the possibility that other posttranscriptional or post-translational modifications of the expressed HDAC that render
them less active, resulting in no overall change in total brain HDAC activity.
Pyruvate: Another Anti-inflammatory Metabolite
Another metabolite that has anti-inflammatory and neuroprotective properties is
pyruvate. The supplementation of pyruvate, or its aliphatic ester ethyl pyruvate,
decreases LPS and hydrogen peroxide-induced microglial activation and promotes
neuronal survival (Kim et al. 2005). In addition, the administration of pyruvate
provides protection against hippocampal neuronal injury following transient cerebral
ischemia in rats (Lee et al. 2001). Pyruvate also boosts extracellular brain glucose
levels and decreases contusion volume and neuronal death in a rat model of traumatic
brain injury (Fukushima et al. 2009). Because acetate-derived acetyl-CoA can inhibit
pyruvate dehydrogenase and lead to the accumulation of brain pyruvate, it is not
unreasonable to suggest that the anti-inflammatory and neuroprotective effect of acetate
may occur at least in part due to the accumulation of pyruvate. It will be interesting to
test whether pyruvate, like acetate, can increase brain acetyl-CoA levels and alter
histone acetylation and pro-inflammatory gene expression. To examine whether
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acetate works through a mitochondrial process, we measured the effect of acetate on
mitochondrial biogenesis but found no alteration in neuronal mitochondrial numbers
following 28 days of acetate supplementation. This, however, does not exclude the
possibility that acetate alters other mitochondrial processes such as tricarboxylic acid
cycle, the energy state, or mitochondrial gene expression. In summary, long-term
acetate supplementation reduced IL-1β expression in vivo by a mechanism that may
involve a distinct site-specific pattern of histone acetylation and/or HDAC expression
in brain. LPS-induced changes in H3K9 acetylation, the expression of HDAC7, and the
pro-inflammatory cytokine IL-1β are potentially key mechanistic targets of acetate
supplementation. Thus physical epigenetic changes and/or direct changes in protein
acetylation may help to explain the functional consequences of acetate supplementation
found in this rat model of neuroinflammation.
The data generated in the in vitro system were informative and inclusive as they
comprised more pro-inflammatory cytokines as well as anti-inflammatory cytokines
that could not be measured reliably in vivo because of the dilution of these molecules in
whole brain homogenates. We demonstrated that acetate treatment reverses the LPSinduced reduction in H3K9 acetylation and decreases pro-inflammatory cytokines in
microglia in vitro. Moreover, acetate treatment increased the transcription of the antiinflammatory cytokines TGF-β1 and IL-4, suggesting that acetate-induced histone
modulation may influence more strongly the expression of anti-inflammatory cytokines
in this model considering histone hyperacetylation is conventionally linked to increased
gene expression. We also demonstrated the time-dependent effects of LPS and acetate
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treatment on MAPK activation. In addition, acetate treatment reduced LPS-induced
increases in total NF-κB p65 protein level, serine 468 phosphorylation, and increased
its acetylation at lysine 310. These data suggest that acetate metabolism can modulate
cytokine balance in microglia toward a more anti-inflammatory state which correlates
to increases in both histone and non-histone protein acetylation.
Possible Mechanisms by which Acetate may Interfere with Translation
The differential effect of acetate treatment on mRNA and protein levels
suggests that the reduction in pro-inflammatory cytokines may be due to a disruption in
mRNA translation rather than gene transcription or pro-inflammatory cytokine
turnover. Translation involves the interaction of mRNA with various subsets of
proteins which, we speculate, may be regulated by acetylation. For example, nuclear
mRNA binds to nuclear proteins that transport mRNA to the cytosol. Some of these
proteins repress translation by interfering with the binding of mRNA to ribosomal
subunits (Wells 2006). Similarly, the integrity of mRNA is modulated by mRNA
stabilizing proteins (Kohn et al. 1996). It is possible that acetylation may alter the
expression and/or activity of mRNA-binding and/or stabilizing proteins. Of particular
interest is cytosolic polyadenylation element-binding protein (CPEB) expressed both in
neuroglia and neurons which prevents the formation of the translation initiation
complex and represses translation (Theis et al. 2003, Mendez & Richter 2001). CPEB
is regulated by phosphorylation (Atkins et al. 2004) however the effect that acetylation
has on its activity remains unknown. Further, the eukaryotic initiation factor 5A
(eIF5A), which regulates initiation and elongation, contains a polyamine-lysine
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conjugated amino acid “hypusine” that is essential to its activity (Zanelli et al. 2006,
Gregio et al. 2009, Saini et al. 2009) and is inactivated following acetylation by
spermidine/spermine acetyltransferase 1 (Lee et al. 2011). In addition, acetylation by a
histone acetyltransferase PCAF leads to eIF5A accumulation in the nucleus that
prevents translocation to the cytosol and in turn disrupts translation (Ishfaq et al. 2012).
All of which suggests that acetylation may be involved in the regulation of mRNA
translation. Acetate treatment may also reduce pro-inflammatory cytokine levels but
not mRNA by increasing protein turnover. A number of histone acetyltransferases
possess intrinsic ubiquitin-conjugating activity and are associated with ubiquitin
transferases in multiprotein complexes that stimulate degradation (Sadoul et al. 2008).
Further, acetylation of the translation elongation factor (E2F1) (Galbiati et al. 2005)
and the hypoxia-inducible factor 1α (HIF-1) at lysine 532 enhances their ubiquitination
and degradation (Jeong et al. 2002). Thus, it is plausible that non-histone protein
acetylation may alter mRNA translation and the turnover of pro-inflammatory
cytokines in activated microglia. These speculations may potentially explain why
acetate treatment reduces the levels of pro-inflammatory cytokine protein and not
mRNA.
The Dynamic Balance between Pro- and Anti-inflammatory Cytokines
An increase in pro-inflammatory cytokine production is generally considered
deleterious based on their involvement in a wide number of neurological and nonneurological disorders. IL-1β, among other cytokines, is expressed in brain at low
levels under physiological conditions and contributes to the control of metabolism
118

(Grossberg et al. 2011), temperature regulation (Huang et al. 2010b), synaptic plasticity
and neuronal transmission (Vitkovic et al. 2000). However, IL-1β is produced in high
levels in many pathological conditions that include ischemic stroke (Legos et al. 2000),
Alzheimer’s disease (Griffin et al. 1989, Shaftel et al. 2008), Down syndrome (Griffin
et al. 1989), multiple sclerosis (McGuinness et al. 1997), Parkinson’s disease (Parish et
al. 2002), epilepsy (Pernot et al. 2011), amyotrophic lateral sclerosis (Meissner et al.
2010), and HIV-associated dementia (Zhao et al. 2001). Co-cultures of primary rat
cortical neurons with LPS-activated microglia results in neuronal death which can be
largely blocked using the naturally occurring IL-1 receptor antagonist IL-1ra (Li et al.
2003). Not surprisingly, suppression of pro-inflammatory cytokines is associated with
improved behavioral and cognitive endpoints in animal models of neurodegenerative
diseases (Hu et al. 2007, Lloyd et al. 2008). All of which suggests that IL-1β has an
important role in the progression of neuroinflammation (Basu et al. 2004). Upon
injury, activated microglia produce inflammatory mediators which lead to activation
and proliferation of astrocytes. Likewise, activated astrocytes release inflammatory
mediators, leading to further inter-glial communication, that if left unchecked results in
neuronal bystander lysis (Streit et al. 1999). IL-1β is a major signaling molecule and is
involved in both neuronal-glial and inter-glial interactions which can increase
microglial proliferation in mixed glial cultures, but not in isolated microglia cultures
(Ganter et al. 1992), bolstering the notion that microglial activation is at least in part
dependent on interactions with neighboring astrocytes (Kim et al.). Therefore,
disruption of the IL-1β system using anti-IL-1β antibodies, receptor blockade, or
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interfering with activation by enzymatic cleavage ameliorates neuroinflammation and
delays neurodegeneration (Labow et al. 1997).
In a mouse model of septic shock, the histone deacetylase inhibitor SAHA
increases H3K9 acetylation and inhibits TNF- and IL-1β gene expression in lung
tissue (Li et al. 2009). This supports the premise that the reduction in the proportion of
H3K9 is indeed associated with the LPS-induced neuroinflammation, and that
increased H3K9 acetylation can be linked to reducing the pro-inflammatory cytokines
expression. However, pro-inflammatory cytokine expression in microglia is controlled
directly by p38 MAPK downstream of the toll-like receptor 4 complex and is
modulated by inhibitors selective for this kinase (Bachstetter et al.). Further, p38
MAPK is associated with other regulatory kinases that are potentially modified posttranslationally by acetylation reactions. For example, HDAC inhibition increases the
acetylation of MAPK- phosphatase 1 that promotes complex formation between MAPK
phosphatase-1 and p38 MAPK. This results in a reduction in phosphorylated p38
MAPK and a reduction in cytokine formation (Cao et al. 2008). Mechanistically, it is
not known whether the net anti-inflammatory effect of HDAC inhibition is the result of
alterations in pro-inflammatory gene expression or a direct result of modulating the
acetylation state of accessory proteins involved in toll-like receptor signaling.
Therefore, it is not clear at this point as to whether the treatment effect found in vivo on
IL-1β expression, on IL-6 in vitro in LPS-stimulated microglia, and on TNF-α in LPSstimulated astrocytes is a direct result of decreasing p38 MAPK phosphorylation or an
indirect effect by modulating gene expression.
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On the other hand, IL-4, IL-10, and TGF-β1 share features of anti-inflammatory
and neuroprotective actions that can be attributed to downregulating glial production of
pro-inflammatory cytokines and/or attenuating their secondary release. IL-4 reduces
the production of inflammatory mediators, including inducible nitric oxide (NO)
synthase, TNF-α, IL-1β, cyclooxygenase 2, and macrophage chemoattractant protein-1
by activated microglia in vivo and in vitro (Ledeboer et al. 2000, Furlan et al. 2000). In
addition, TGF-β has a neuroprotective effect by regulating Bad (pro-apoptotic) and Bcl2 and Bcl-x1 (anti-apoptotic) proteins (Dhandapani & Brann 2003). Further, antiinflammatory cytokines reduce the expression levels of the pro-inflammatory cytokines
in LPS-stimulated microglial-astroglial co-cultures (Ledeboer et al. 2000). Endogenous
and exogenous TGF-β1 and β2 suppress the production of NO but not IL-1β, IL-6 or
TNF-α and exogenous IL-4 downregulates NO, IL-6 and TNF-α, but not IL-1β
(Ledeboer et al. 2000). Our findings showing that LPS stimulation upregulated IL-10
is not counterintuitive, because stimulation of an inflammatory response can lead to
upregulation of both conventional pro-inflammatory and anti-inflammatory mediators
as a biological self-checking mechanism. In this regard, IL-10 inhibits the LPSinduced increase of IL-1β and TNF-α (Sawada et al. 1999) and IL-10 release by LPSstimulated microglia increases simultaneously with TNF-α (Seo et al. 2004). The
multiplicity of receptors, signaling cascades, cellular and subcellular targets, and
various experimental designs all demonstrate the complexity of how anti-inflammatory
cytokines can regulate the transcription and/or translation of the pro-inflammatory
cytokines.
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A dynamic balance exists between the pro- and anti-inflammatory cytokines,
both of which are generated upon exposure to injury or infection. The duration and net
effect of interactions between these opposing molecular groups determines the outcome
of the immune response. Pathologies arise from shifting this dynamic balance in one
direction or the other. For example, excessive pro-inflammatory cytokines are linked to
neuroinflammation and degeneration as mentioned earlier, while excessive antiinflammatory cytokines are conversely associated with susceptibility to systemic
infections (Kasai et al. 1997, Munoz et al. 1991).
Non-histone Targets of Acetylation
Lysine acetylation is a common post-translational modification that occurs on
both histones as well as non-histone proteins. Histone acetylation is conventionally
linked to alteration of gene expression. Non-histone targets of acetylation include
cytoskeletal proteins and transcription and nuclear import factors. Acetylation of these
targets have many functional consequences including altering subcellular localization,
DNA-binding, transcriptional activity, protein-protein interaction and protein stability
(Sadoul et al. 2008, Glozak et al. 2005). Acetyltransferases use acetyl-CoA as acetyl
donor for post-translational acetylation reactions on lysine and arginine residues which
can lead to structural and functional consequences in proteins. The functional
consequences of acetylation depend on where exactly within the protein acetylation
takes place. For example, NF-κB p65 acetylation at lysines 218, 221 and 310 increases
nuclear localization, while acetylation at 122 and 123 reduces the binding affinity of
p65 to DNA which promotes IκB-p65 interaction and nuclear export (Chen et al. 2002,
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Huang et al. 2010a). These examples give an idea on the intricacy of reactions and
functional consequences based of acetylation. We have demonstrated that, in LPSstimulated primary astrocyte cell cultures, acetate treatment decreases the basal levels
of NF-κB p65 phosphorylation at serine 536 while not altering p65 phosphorylation at
serine 468 or acetylation at lysine 310. In this regard, phosphorylation of serine 536
lowers the affinity of p65 to IκBα leading to NF- κB translocation into the nucleus and
enhanced activity (Buss et al. 2004, Bohuslav et al. 2004). Therefore, acetate
treatment-mediated reduction in p65 phosphorylation at 536 may be responsible in part
for the anti-inflammatory effect of acetate supplementation on LPS-activated astrocytes
we observed in vivo (Reisenauer et al. 2011). Because p65 phosphorylation at serine
536 stimulates subsequent acetylation at lysine 310 (Hoberg et al. 2006, Chen et al.
2005b), this could explain why acetate does not increase acetylation at lysine 310 in
astrocytes, unlike in microglia. Regardless, since post-translational modifications of
NF-κB have diverse functional consequences (Huang et al. 2010a), further experiments
need to be performed to determine the effect of acetate treatment on the different
functional aspects of NF-κB in both LPS-stimulated microglia and astrocyte cultures.
MAPK signaling -another example of non-histone targets of acetylation- is
inducible by pro-inflammatory cytokines and also regulates their transcription and
translation. For example, MAPK signaling regulates the production of IL-8 in response
to IL-1 and osmotic shock (Shapiro & Dinarello 1995), and regulates the production of
IL-6 in response to TNF-α (Beyaert et al. 1996). Furthermore, interferon-β reduces
traumatic spinal cord injury-induced ERK hyperphosphorylation and is associated with
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functional recovery (Ito et al. 2009). Inhibition of MAPK p38 and ERK reduces edema
and the inflammatory mediator matrix metalloproteinase-9 after brain trauma (Mori et
al. 2002), the infarct size (Sugino et al. 2000), iNOS, TNF-α, and cyclooxygenase-2
expression (Piao et al. 2003) in ischemia, and the neurological deficits after transient
(Legos et al. 2001) and permanent (Barone et al. 2001) ischemia. Animals with genetic
deletion of one of the MAPK accessory proteins show diminished IL-6 and TNF-α
production in response to LPS stimulation (Kotlyarov et al. 1999).
Earlier studies demonstrated that a MAPK phosphatase is activated by certain
lysine acetylation which leads to inactivation of MAPK signaling pathway, providing
an important link between acetylation and phosphorylation in the regulation of
neuroinflammation (Cao et al. 2008). Because MAPK signaling can be altered by
acetylation, we studied whether acetate treatment alters MAPK phosphorylation
(activation) in LPS-stimulated BV-2 microglia and primary astrocyte cell cultures. We
have showed that acetate reduces LPS-induced MAPK p38 phosphorylation and basal
level phosphorylation of ERK1/2 in astrocytes which may be attributable to acetylation
of MAPK phosphatase-1. In BV-2 microglia, the effect of LPS on MAPK
phosphorylation in BV-2 microglia was time-dependent, as was the ability of acetate
treatment to reduce LPS-induced p38 and JNK phosphorylation. LPS increased
phosphorylated p38 at 4 hr and phosphorylated JNK at 2 and 4 hr, whereas acetate
treatment reduced phosphorylated p38 and JNK only at 2, but not 4, hr. We did not
observe an increase in MAPK activation at 0.5 or 1 hr unlike other studies (Schumann
et al. 1996, Kraatz et al. 1998). However, this may be due to our using a lower
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concentration of LPS or may demonstrate a cell-type specific response. These data are
important in the light of the role that MAPK signaling has in neuropathologies. While
the therapeutic effect of acetate supplementation is demonstrated in the in vivo studies
(Reisenauer et al. 2011), these present results further strengthen our understanding of
the possible therapeutic mechanism(s) involved in modulating cytokine expression by
increasing acetate metabolism. Therefore, because the effect of acetate treatment on
the LPS-induced MAPK p38 phosphorylation in BV-2 microglia is transient, the effect
of acetate treatment on cytokine release may be due to the synergistic effect of other
possible mechanisms.
NF-κB -another example of non-histone targets of acetylation- is acetylated on
p65 subunit which modulates nuclear translocation, DNA binding, and transcriptional
activity (Chen et al. 2001, Chen et al. 2002, Huang et al. 2010a). Our studies showed
that acetate treatment induced p65 hyperacetylation at lysine 310 in LPS-stimulated
BV-2 microglia. This is of interest because p65 interacts with HDAC1, 2 and 3, but
only HDAC3 deacetylates p65 (Kiernan et al. 2003, Chen et al. 2001) which is
downregulated with long-term acetate supplementation (Figure 11). Therefore, the
effect that acetate metabolism has on HDAC3 expression may help to explain the
hyperacetylation of p65 at lysine 310 observed in this study. The acetylation of p65
may be associated with anti-inflammatory outcomes as it represses transcriptional
activity, reduces binding to κB-DNA, and facilitates its interaction with IκB that
increases p65 export to the cytoplasm. Because acetylated p65 accumulates in the
cytoplasm suggests that post-activation turn-off of NF-κB-dependent transcription is
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regulated, at least in part, by acetylation (Kiernan et al. 2003). However, β-amyloid
toxicity increases hyperacetylated p65 at lysine 310 in microglia, which is reversed by
sirtuin 1 over-expression and stimulation (Chen et al. 2005a). This suggests that
changes in the activity and expression of the of the sirtuins and class I HDAC can
differentially modulate NF-κB-mediated inflammatory phenotype, possibly as a result
of differing inflammatory stimulation or differing intercellular regulation points.
Alternately, acetate treatment-induced p65 hyperacetylation in the presence of LPS
may be linked to pro-inflammatory signaling that is generally outweighed by the other
anti-inflammatory mechanisms. Regardless, the functional consequences of posttranslational modification of p65 are diverse and specific to the modification and the
residue involved (Huang et al. 2010a). Future studies are necessary to determine the
impact that acetylation of p65 has on NF-κB functionality in this model.
Acetate-mediated Global and Gene-specific Epigenetic and Expression
Modulation
Whereas acetate treatment alters histone acetylation at histones H3K9, H4K8
and H4K16 after a single oral dose and long-term supplementation, LPS alters only
acetylated H3K9 in our in vivo experimental paradigm where it reduces acetylated
H3K9 by 2-fold and acetate treatment reverses it to a hyperacetylation state (Soliman et
al. 2012b). Because of this as well as other reports implicating H3K9 in
neuroinflammation and neuroglial activation (Govindarajan et al. 2011, Silva et al.
2012, Zhang et al. 2008), we chose to focus on this epigenetic marker for our later in
vitro experiments. In LPS-stimulated microglia, acetate treatment also reverses LPSinduced H3K9 hypoacetylation similar to that found in vivo (Soliman et al. 2012a). In
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contrast, in LPS-stimulated astrocytes, acetate treatment increases H3K9 acetylation in
the presence and absence of LPS, but LPS itself does not alter acetylated H3K9. For
this reason, we decided to carry out our chromatin immunoprecipitation analysis with
BV-2 microglia cultures, where LPS is altered by both LPS and acetate treatment.
Acetate treatment reverses LPS-induced increases in Cox-1, Cox-2 and NF-κB
p65 protein levels, IL-1β protein and not mRNA, and increases IL-4 mRNA. In an
attempt to determine whether acetate treatment-induced global H3K9 hyperacetylation
is involved in the regulation of these inflammatory mediators at the gene levels, we
measured H3K9 acetylation at the promoters of these genes of interest using chromatin
immunoprecipitation. The enrichment levels of acetylated H3K9 were increased
around the promoter regions for the genes coding for Cox-1 and 2, IL-1β and NF-κB
p65, but not IL-4, all of which were largely unaffected by LPS. This suggests that
acetate-induced H3K9 acetylation may potentially contribute to the effect of treatment
on the expression of these specific genes. Alternatively, the effect of acetate treatment
on gene expression can possibly be linked to acetylation of non-histone transcription
factors as discussed earlier, or other acetate treatment-mediated histone acetylation
changes such as H4K8 or H4K16. These results warrant more experiments to evaluate
the involvement of other histone markers in the acetate-treatment mediated gene
expression changes.
Since histone acetylation is conventionally associated with enhanced gene
expression (Strahl & Allis 2000), we speculate that the increases in H3K9 acetylation
may be instrumental in upregulating the transcription of anti-inflammatory cytokines,
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as found in our studies. Interestingly, LPS did not alter H3K9 acetylation in astrocytes
unlike our other results showing that LPS infusion over 28 days decreases H3K9
acetylation by 50% in whole brains from a rat model of neuroinflammation (Soliman et
al. 2012b) and in LPS-stimulated primary and BV-2 microglia. This can potentially be
attributed to the different overall acetate concentrations (and thus acetate-derived
acetyl-CoA) in vivo and in vitro, or the in vivo results representing the combined effects
in all cell types in the brain. Our data also demonstrate a correlation between acetate
treatment-induced inhibition of pro-inflammatory cytokine release and hyperacetylation
of H3K9 and p65 at lysine 310.
H3K9 can also be modified by methylation where methylated H3K9 is
associated with gene repression, contrary to acetylated H3K9 that is associated with
active gene expression (Rice & Allis 2001). In this regard, the enrichment of
methylated H3K9 at the promoter region of opioid receptors is linked to a decrease in
opioid receptor transcription in mice fed a high fat diet (Vucetic et al. 2011). Similarly,
genome-wide mapping demonstrates that an increase H3K9 acetylation corresponds
with areas of transcription activity (Shin et al. 2012). H3 methylation is more
predominant in areas of enriched acetylated H4, unlike methylated H4 which is more
evident in less acetylated chromatin regions (Annunziato et al. 1995). The functional
outcome of this interplay regarding gene expression control and the individual genes
involved is not clearly known, but sheds the light on the intricacy of the posttranslational modifications of histones. It is also possible that H3K9 hyperacetylation
may alter the expression and/or activity of effector proteins involved in translation,
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which may help to explain the decrease in pro-inflammatory cytokines in the absence
of a reduction in their mRNA levels.
To address non-specific effects of acetate on gene expression, we performed an
rt-PCR array to determine the simultaneous changes in 84 genes involved in both the
innate and adaptive immune responses. The expression of only six genes was altered
by more than 0.5-fold. Only four genes did show more than a 2–fold change;
adenosine receptor A2a, MAPK p38, TNF-α, and IL-1 receptor antagonist suggesting
that acetate supplementation can influence the expression of genes involved in adaptive
and innate immune responses. None of these changes were statistically significant,
with the exception of adenosine A2a mRNA which was increased by 8 fold. The
importance of this experiment is that it shows that acetate treatment alters the
expression of selected genes and does not induce global gene expression changes.
Astrocytes Involvement in the Inter-glial Communication in Neuroinflammation
Astrocytes possess a number of physiological functions including regulation of
blood flow, fluid, ion and transmitter homeostasis, modulation of synaptic functions,
and supporting the blood brain barrier (Sofroniew & Vinters 2010). The immune
functions of the astrocytes are recognized as astrocytes are an abundant source of proinflammatory cytokines and other as inflammatory mediators in brain injury and
infection (Sofroniew & Vinters 2010, Dong & Benveniste 2001, Gorina et al. 2009,
Gorina et al. 2011) and reactive astrogliosis is a pathological component of numerous
neurological discords (Hamby & Sofroniew 2010, Sofroniew & Vinters 2010).
Furthermore, glial communication plays a crucial role in sustaining a
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neuroinflammatory response and can eventually lead to neuronal bystander death if left
unchecked (Tian et al. 2012, Hamby & Sofroniew 2010, Streit et al. 1999). This
crosstalk also involves beneficial effects; for example, astrocytic factors upregulate
microglia-derived anti-oxidants and thus reduce microglial reactive oxygen species
generation (Min et al. 2006). Likewise, astrocyte-conditioned media rapidly reduce
interferon-γ-stimulated microglia-derived inflammatory mediators such as iNOS (Kim
et al. 2010) and stimulate microglial release of the pro-survival mediator brain-derived
neurotrophic factor (Yang et al. 2012). Downregulating the astrocytes-derived
inflammatory response protects neurons from the potential of excessive uncontrolled
pro-inflammatory cytokines (Hamby & Sofroniew 2010). In addition, it can disrupt
neuroglia communication and mutual activation, and therefore further averts neuronal
damage. We demonstrated that acetate treatment reduces pro-inflammatory cytokine
levels in a rat model of neuroinflammation, and in vitro in LPS-stimulated microglia
and astrocytes, which can explain the attenuation of LPS-induced glial activation
observed with acetate supplementation in vivo (Reisenauer et al. 2011).
The Differences between the Effects of Acetate Treatment in Microglia and
Astrocyte Cultures
Interestingly, throughout our cumulating work, we have observed many
neuroglial cell type-specific similarities as well as discrepancies in terms of their
response to acetate treatment and LPS challenge. Similarities include acetate treatment
reducing LPS-induced microglial and astrocyte activation in vivo, increasing H3K9
acetylation, upregulating anti-inflammatory cytokine IL-4 and TGF-β1 mRNA, and
returning LPS-induced NF-κB p65 and Cox-1 protein levels to control levels in both
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cell types in vitro. Moreover, acetate treatment reduces pro-inflammatory cytokines
IL-1β, IL-6 and TNF-α protein but not mRNA in both cell types, suggesting that
treatment decreases pro-inflammatory cytokine levels mainly by interfering with
translation of mRNA rather than modulating transcription, or by stimulating protein
turnover. Differences between the astroglial and microglia responses include LPS
reducing H3K9 acetylation by 2-fold, increasing IL-6 by 1.3-fold, increasing JNK
phosphorylation by 2-fold, and decreasing PLCβ1 protein level only in microglia.
Moreover, whereas MAPK p38 phosphorylation is increased by LPS both in microglia
and astrocytes, it is reduced by acetate treatment at 4 hr in astrocytes cell cultures only.
In addition, acetate treatment increases NF-κB p65 acetylation at lysine 310 by 3.5 fold,
and reverses LPS-induced increases in phosphorylation at serine 468 of p65 and Cox-2
protein level only in microglial cell culture, whereas only in astrocytes does acetate
treatment decrease sPLA2 IIA, PLCβ1, LPS-induced cPLA2 phosphorylation and PGE2
release, and basal levels of NF-κB p65 phosphorylation at 536. ERK1/2
phosphorylation increases by acetate treatment only in the presence of LPS in microglia
cultures, and is reduced beyond control levels with acetate treatment in astrocyte
cultures. All of which demonstrates clear cell type-specific responses to acetate
treatment despite the similar overall anti-inflammatory outcome evidenced by the
reduction in the LPS-induced activation in vivo and the shift of the inflammatory
cytokine balance toward a more anti-inflammatory state in vitro and in vivo. This is
further supported by other reports showing the distinctive responses of astrocytes and
microglia to injury, infection, inflammation and other anti-inflammatory agents (Lee et
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al. 2010, Lu et al. 2010). Because acetate treatment reverses the LPS-induced MAPK
p38 phosphorylation and the basal levels of phosphorylated ERK1/2 in astrocyte and
not in microglial cultures, we speculate that interruption of MAPK signaling plays a
stronger role in the anti-inflammatory effect of acetate treatment in astrocytes.
Conversely, because H3K9 acetylation in reduced by LPS and reversed with acetate
treatment in microglia, it is possible that the epigenetic mechanisms are more
influential in microglia. This premise is promising for the potential of selectively
downregulating MAPK signaling in only one cell type without impeding its
physiological functions in other cell types, as opposed to universal inhibitors of MAPK
signaling. This adds to the advantage of acetate treatment being safe and welltolerated. In this regard, clinical trials using glyceryl triacetate to induce acetate
supplementation in patients with Canavan’s disease show that it does not produce
biochemical or metabolic abnormalities (Madhavarao et al. 2009, Segel et al. 2011).
Likewise, animal studies using larger doses of glyceryl triacetate show that acetate
supplementation is well-tolerated and cause no apparent toxicity (Mathew et al. 2005).
In vivo, the discrepancy in the glial responses to acetate treatment, which
partially reduces LPS-mediated microglial activation while completely reducing
astrocyte activation, may be attributed to astrocytes being more efficient at the uptake
and/or utilization of acetate, or the continual LPS stimulation to which microglia may
be more sensitive. This could potentially explain why acetate treatment interrupts more
inflammatory reactions in astrocytes than it does it microglia as demonstrated by the
selective effect of acetate on MAPK, cPLA2 phosphorylation, sPLA2 IIA, PLCβ1 and
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PGE2 release in astrocyte. These speculations pave the road for further studies
determining other cell type-specific mechanism of the anti-inflammatory effect of
acetate.
Eicosanoid Signaling Alteration in the Light of MAPK and Cytokine Changes
To broaden our understanding of the mechanisms of the anti-inflammatory
effect of acetate in vivo, we studied the effect of acetate treatment on eicosanoid
signaling known to be associated with neuroinflammatory and neurodegenerative
conditions (Lima et al. 2012, Sun et al. 2010) in BV-2 microglia and primary astrocyte
cultures following LPS stimulation. Acetate treatment did not alter LPS-induced
cPLA2 phosphorylation and reversed LPS-induced reduction in PLCβ1 and increases in
Cox-1 and Cox-2 in BV-2 microglia. In LPS-stimulated primary astrocytes, acetate
treatment reduced sPLA2 IIA, PLCβ1 in the presence of LPS and reversed the LPSinduced cPLA2 phosphorylation and Cox-1 levels while not altering LPS-increased
Cox-2. Further, acetate treatment reversed LPS-elevated PGE2 secretion in astrocyte,
which was not altered in BV-2 microglia by either LPS or acetate treatment. The
enrichment levels of acetylated H3K9 were measured at the promoters of the genes for
Cox-1 and 2 and were found to be increased by acetate treatment and largely unaltered
by LPS stimulation. These data suggest that acetate treatment can modulate eicosanoid
signaling in neuroglial cell type-distinct mechanisms, which may potentially involve
H3K9 acetylation.
Of interest, acetate reduces sPLA2 IIA and LPS-induced cPLA2 phosphorylation
in astrocytes and not BV-2 microglia. Because cPLA2 is a substrate for
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phosphorylation by MAPK p38 (Hiller & Sundler 1999, Kramer et al. 1996) and ERK
(Hiller & Sundler 1999), both of which are inhibited by acetate treatment in astrocytes
and not BV-2 microglia, it is possible that acetate treatment reverses cPLA2
phosphorylation primarily by reducing MAPK p38 and ERK activity. In addition,
acetate treatment reduces LPS-induced elevations of TNF-α and IL-1β, both of which
upregulate cPLA2 phosphorylation (Jupp et al. 2003) and sPLA2 IIA level and activity
(Adibhatla & Hatcher 2007) which may contribute to the reduction of cPLA2
phosphorylation with acetate treatment. Although plausible in astrocytes, this does not
explain why acetate treatment does not reduce LPS-induced cPLA2 phosphorylation in
BV-2 microglia in this study, since acetate treatment reduces IL-1β and TNF-α in both
LPS-stimulated BV-2 microglia and astrocyte cultures. The complete attenuation of
LPS-induced PGE2 in astrocytes and not in BV-2 microglia by acetate treatment can
potentially be due to completely reducing cPLA2 phosphorylation only in astrocytes.
These data do not exclude the possibility of alterations regarding the enzyme activities
and membrane translocation.
Conclusion
In conclusion, these studies significantly broadened our understanding of the
specific molecular and cellular effects of acetate treatment in in vivo and in vitro
models of inflammation. We have optimized in vitro microglia and astrocyte systems
that reproduce the main findings from a rat model of neuroinflammation. Specific key
inflammatory mediators have been identified that can be altered by acetate treatment in
neuroglial cell type-specific patterns in microglia and astrocyte. Moreover, these
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results describe epigenetic changes both on the global and gene-specific levels, shifting
of the inflammatory cytokine balance towards a more anti-inflammatory phenotype,
and modulation of certain signaling transduction pathways by acetate treatment. Future
studies will test the effect of acetate treatment on the behavioral deficits in animal
models of neurodegenerative diseases such as a triple transgenic mouse model of
Alzheimer’s disease, the functional consequences of NF-κB modifications, and the
changes in other histone targets and their modifications.
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